|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine] results in increased expression of APOA1 protein |
CTD |
PMID:16324916 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Apoa2 |
apolipoprotein A2 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine] results in decreased expression of APOA2 protein |
CTD |
PMID:16324916 |
|
NCBI chr13:89,596,872...89,598,805
Ensembl chr13:89,597,138...89,598,802
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine] results in decreased expression of APOB protein |
CTD |
PMID:16324916 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Apoc1 |
apolipoprotein C1 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in increased expression of APOC1 protein |
CTD |
PMID:16324916 |
|
NCBI chr 1:80,606,638...80,609,921
Ensembl chr 1:80,606,638...80,609,921
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC2 protein |
CTD |
PMID:16324916 |
|
NCBI chr 1:80,589,023...80,593,991
Ensembl chr 1:80,589,023...80,594,136
|
|
G |
Apoc3 |
apolipoprotein C3 |
multiple interactions |
ISO |
[Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein |
CTD |
PMID:16324916 |
|
NCBI chr 8:50,529,318...50,531,498
Ensembl chr 8:50,529,318...50,531,498
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[Caffeine co-treated with Ephedrine] results in increased cleavage of CASP3 protein |
CTD |
PMID:15537744 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD mRNA]; [Caffeine co-treated with Ephedrine] affects the reaction [Sodium Glutamate results in decreased expression of CFD protein] |
CTD |
PMID:2307116 |
|
NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Ephedrine results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
EXP |
[Caffeine co-treated with Ephedrine] results in increased phosphorylation of H2AX protein |
CTD |
PMID:15537744 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions increases export |
EXP |
[Epinephrine co-treated with [verlukast results in decreased activity of ABCC1 protein]] results in increased abundance of Glutathione Disulfide; [verlukast results in decreased activity of ABCC1 protein] which promotes the reaction and affects the abundance of Epinephrine metabolite ABCC1 protein results in increased export of Epinephrine metabolite |
CTD |
PMID:19053318 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Aco2 |
aconitase 2 |
increases expression |
EXP |
Epinephrine results in increased expression of ACO2 protein |
CTD |
PMID:19464573 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Actn1 |
actinin, alpha 1 |
increases expression |
EXP |
Epinephrine results in increased expression of ACTN1 protein |
CTD |
PMID:19464573 |
|
NCBI chr 6:103,376,557...103,470,497
Ensembl chr 6:103,375,799...103,470,555
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions increases activity affects binding |
EXP ISO |
[Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased transport of Calcium; Epinephrine binds to and results in increased activity of ADRA1A protein Epinephrine results in increased activity of ADRA1A protein [Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1A protein; Epinephrine inhibits the reaction [ADRA1A protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium] Epinephrine binds to ADRA1A protein |
CTD |
PMID:8183249 PMID:15306222 PMID:15672411 PMID:20030735 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
multiple interactions increases activity |
ISO |
[Epinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1B protein; Epinephrine inhibits the reaction [ADRA1B protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium] |
CTD |
PMID:15306222 PMID:20030735 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
affects binding increases activity multiple interactions |
ISO |
Epinephrine binds to ADRA1D protein Epinephrine results in increased activity of ADRA1D protein [Epinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1D protein; Epinephrine inhibits the reaction [ADRA1D protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium] |
CTD |
PMID:8183249 PMID:15306222 PMID:20030735 |
|
NCBI chr 3:124,129,558...124,145,566
Ensembl chr 3:124,129,558...124,145,566
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
increases activity multiple interactions |
EXP ISO |
Epinephrine results in increased activity of ADRA2A protein Epinephrine promotes the reaction [GNB2 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNB4 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG12 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG2 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG3 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG4 protein binds to ADRA2A protein] [Epinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2A protein; Epinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan] |
CTD |
PMID:17341653 PMID:17680988 PMID:20030735 PMID:30737458 |
|
NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
|
|
G |
Adra2b |
adrenoceptor alpha 2B |
multiple interactions |
ISO |
[Epinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2B protein; Epinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan] |
CTD |
PMID:17680988 PMID:20030735 |
|
NCBI chr 3:119,805,941...119,809,987
Ensembl chr 3:119,805,941...119,809,987
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
multiple interactions |
ISO |
[Epinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2C protein; Epinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan] |
CTD |
PMID:17680988 PMID:20030735 |
|
NCBI chr14:80,730,307...80,732,010
Ensembl chr14:80,730,307...80,732,010
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO EXP |
[CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased activity of Epinephrine Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein] [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Epinephrine binds to and results in increased activity of ADRB1 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein] |
CTD |
PMID:8096834 PMID:12010770 PMID:14730417 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions affects response to substance increases activity |
ISO EXP |
[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; carvedilol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Epinephrine binds to and results in increased activity of ADRB2 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Epinephrine promotes the reaction [GRK2 protein results in increased phosphorylation of ADRB2 protein]; Epinephrine promotes the reaction [GRK5 protein results in increased phosphorylation of ADRB2 protein]; Epinephrine results in increased phosphorylation of and results in increased localization of ADRB2 protein; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein] [Epinephrine results in increased activity of ADRB2 protein] which results in increased secretion of Histamine ADRB2 affects the susceptibility to Epinephrine |
CTD |
PMID:1389726 PMID:11164953 PMID:12920204 PMID:14722251 PMID:14730417 PMID:16026475 PMID:16225854 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
EXP ISO |
Epinephrine binds to and results in increased activity of ADRB3 protein [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Epinephrine binds to and results in increased activity of ADRB3 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:1682311 PMID:7815362 PMID:14730417 |
|
NCBI chr16:69,003,541...69,006,632
Ensembl chr16:69,003,868...69,006,632
|
|
G |
Ak2 |
adenylate kinase 2 |
decreases expression multiple interactions |
EXP |
Epinephrine results in decreased expression of AK2 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of AK2 protein |
CTD |
PMID:19464573 |
|
NCBI chr 5:147,185,474...147,204,050
Ensembl chr 5:147,185,474...147,204,050
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[Epinephrine co-treated with INS protein] results in increased phosphorylation of AKT1 protein |
CTD |
PMID:32305330 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions increases activity |
EXP |
Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Dactinomycin inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein] |
CTD |
PMID:2860926 |
|
NCBI chr 4:78,496,043...78,515,582
Ensembl chr 4:78,496,043...78,515,584
|
|
G |
Aqp7 |
aquaporin 7 |
affects localization multiple interactions increases expression |
ISO |
Epinephrine affects the localization of AQP7 protein INS1 inhibits the reaction [Epinephrine results in increased expression of AQP7 mRNA] |
CTD |
PMID:10777495 |
|
NCBI chr 5:57,358,297...57,372,332
Ensembl chr 5:57,358,327...57,372,239
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
increases expression |
EXP |
Epinephrine results in increased expression of ATP5F1A protein |
CTD |
PMID:19464573 |
|
NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
decreases expression |
ISO |
Epinephrine results in decreased expression of BMP2 mRNA; Epinephrine results in decreased expression of BMP2 protein |
CTD |
PMID:31520687 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
C1qbp |
complement C1q binding protein |
multiple interactions increases expression |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of C1QBP protein Epinephrine results in increased expression of C1QBP protein |
CTD |
PMID:19464573 |
|
NCBI chr10:57,613,876...57,618,527
Ensembl chr10:57,613,879...57,618,527
|
|
G |
Caly |
calcyon neuron-specific vesicular protein |
decreases secretion |
ISO |
CALY protein results in decreased secretion of Epinephrine |
CTD |
PMID:30753204 |
|
NCBI chr 1:212,537,851...212,549,040
Ensembl chr 1:212,537,848...212,549,477
|
|
G |
Car2 |
carbonic anhydrase 2 |
increases expression |
ISO |
Epinephrine results in increased expression of CA2 mRNA |
CTD |
PMID:12729923 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
Atenolol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]; carvedilol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein] Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of CASP3 protein] |
CTD |
PMID:10728402 PMID:19135123 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
decreases response to substance |
ISO |
CAT results in decreased susceptibility to Epinephrine |
CTD |
PMID:25172298 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]; Propranolol inhibits the reaction [Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]] Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Epinephrine inhibits the reaction [Thioglycolates results in increased secretion of CCL3 protein] |
CTD |
PMID:9863660 PMID:12538206 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; 2-methoxyidazoxan inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA] Epinephrine results in increased expression of CCND1 mRNA; Epinephrine results in increased expression of CCND1 protein ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein] |
CTD |
PMID:17680988 PMID:26964897 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
ISO |
Epinephrine results in decreased expression of CEBPB protein |
CTD |
PMID:31520687 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
[methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased abundance of Epinephrine] |
CTD |
PMID:17498763 |
|
NCBI chr 1:123,897,341...124,039,263
Ensembl chr 1:123,899,657...124,039,196
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation multiple interactions |
ISO EXP |
COMT protein results in increased methylation of Epinephrine [COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine; tolcapone inhibits the reaction [[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine] [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Epinephrine |
CTD |
PMID:8821542 PMID:10064789 PMID:11160877 PMID:11248589 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases phosphorylation |
ISO EXP |
ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein] 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; Dietary Fats promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; Epinephrine promotes the reaction [Dietary Fats results in increased phosphorylation of CREB1 protein]; Ketoconazole inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:17680988 PMID:22496244 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions increases abundance |
EXP |
corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein affects the abundance of Epinephrine] CRH results in increased abundance of Epinephrine |
CTD |
PMID:1320258 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]] |
CTD |
PMID:1699227 |
|
NCBI chr 8:62,405,714...62,424,707
Ensembl chr 8:62,405,715...62,424,303
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases phosphorylation multiple interactions |
EXP |
Epinephrine results in increased phosphorylation of CTNNB1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein] |
CTD |
PMID:26964897 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsk |
cathepsin K |
increases expression |
ISO |
Epinephrine results in increased expression of CTSK mRNA |
CTD |
PMID:12729923 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions increases expression |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of CYCS protein Epinephrine results in increased expression of CYCS protein |
CTD |
PMID:19464573 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Dbh |
dopamine beta-hydroxylase |
affects abundance |
ISO |
DBH gene polymorphism affects the abundance of Epinephrine |
CTD |
PMID:16163519 |
|
NCBI chr 3:5,709,236...5,731,895
Ensembl chr 3:5,709,236...5,731,898
|
|
G |
Des |
desmin |
multiple interactions decreases expression |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DES protein Epinephrine results in decreased expression of DES protein |
CTD |
PMID:19464573 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DLAT protein |
CTD |
PMID:19464573 |
|
NCBI chr 8:55,062,549...55,087,832
Ensembl chr 8:55,062,551...55,087,832
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ECHS1 protein |
CTD |
PMID:19464573 |
|
NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057 Ensembl chr 1:212,570,195...212,579,057
|
|
G |
Epha4 |
Eph receptor A4 |
increases phosphorylation |
ISO |
Epinephrine results in increased phosphorylation of EPHA4 protein |
CTD |
PMID:22273509 |
|
NCBI chr 9:83,111,222...83,253,486
Ensembl chr 9:83,111,222...83,253,458
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ETFB protein |
CTD |
PMID:19464573 |
|
NCBI chr 1:98,472,776...98,486,940
Ensembl chr 1:98,472,745...98,486,976
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
affects expression multiple interactions |
EXP |
Epinephrine affects the expression of FABP3 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of FABP3 protein |
CTD |
PMID:19464573 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
Atenolol inhibits the reaction [Epinephrine results in increased expression of FAS protein]; carvedilol inhibits the reaction [Epinephrine results in increased expression of FAS protein] |
CTD |
PMID:10728402 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
Atenolol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]; carvedilol inhibits the reaction [Epinephrine results in increased expression of FASLG protein] |
CTD |
PMID:10728402 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fh |
fumarate hydratase |
increases expression |
EXP |
Epinephrine results in increased expression of FH protein |
CTD |
PMID:19464573 |
|
NCBI chr13:93,651,486...93,677,371
Ensembl chr13:93,651,484...93,677,377
|
|
G |
Foxo1 |
forkhead box O1 |
decreases expression |
ISO |
Epinephrine results in decreased expression of FOXO1 protein |
CTD |
PMID:31520687 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Gnb2 |
G protein subunit beta 2 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [GNB2 protein binds to ADRA2A protein] |
CTD |
PMID:30737458 |
|
NCBI chr12:22,229,079...22,234,096
Ensembl chr12:22,229,079...22,234,096
|
|
G |
Gnb4 |
G protein subunit beta 4 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [GNB4 protein binds to ADRA2A protein] |
CTD |
PMID:30737458 |
|
NCBI chr 2:118,978,965...119,007,877
Ensembl chr 2:118,978,973...119,007,835
|
|
G |
Gng12 |
G protein subunit gamma 12 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [GNG12 protein binds to ADRA2A protein] |
CTD |
PMID:30737458 |
|
NCBI chr 4:97,634,925...97,763,478
Ensembl chr 4:97,657,671...97,760,102
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [GNG2 protein binds to ADRA2A protein] |
CTD |
PMID:30737458 |
|
NCBI chr15:4,748,242...4,853,555
Ensembl chr15:4,850,122...4,853,555
|
|
G |
Gng3 |
G protein subunit gamma 3 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [GNG3 protein binds to ADRA2A protein] |
CTD |
PMID:30737458 |
|
NCBI chr 1:225,033,921...225,035,687
Ensembl chr 1:225,033,921...225,035,687
|
|
G |
Gng4 |
G protein subunit gamma 4 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [GNG4 protein binds to ADRA2A protein] |
CTD |
PMID:30737458 |
|
NCBI chr17:90,266,571...90,316,278
Ensembl chr17:90,266,794...90,315,492
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [GRK2 protein results in increased phosphorylation of ADRB2 protein] |
CTD |
PMID:14722251 |
|
NCBI chr 1:219,536,220...219,544,329
Ensembl chr 1:219,536,220...219,544,328
|
|
G |
Grk5 |
G protein-coupled receptor kinase 5 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [GRK5 protein results in increased phosphorylation of ADRB2 protein] |
CTD |
PMID:14722251 |
|
NCBI chr 1:282,265,371...282,467,842
Ensembl chr 1:282,265,370...282,462,605
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HADH protein |
CTD |
PMID:19464573 |
|
NCBI chr 2:236,353,445...236,395,067
Ensembl chr 2:236,353,445...236,395,067
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions affects localization |
EXP |
Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] affects the localization of HSF1 protein] Epinephrine affects the localization of HSF1 protein |
CTD |
PMID:19135123 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSP90AB1 protein |
CTD |
PMID:19464573 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of HSPA5 protein |
CTD |
PMID:19464573 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
EXP |
Epinephrine results in increased expression of HSPA8 protein |
CTD |
PMID:19464573 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPA9 protein |
CTD |
PMID:19464573 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Hspb6 |
heat shock protein family B (small) member 6 |
decreases expression multiple interactions |
EXP |
Epinephrine results in decreased expression of HSPB6 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPB6 protein |
CTD |
PMID:19464573 |
|
NCBI chr 1:89,008,117...89,010,256
Ensembl chr 1:89,008,117...89,010,256
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
decreases expression multiple interactions |
EXP |
Epinephrine results in decreased expression of IDH2 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of IDH2 protein |
CTD |
PMID:19464573 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Epinephrine promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] |
CTD |
PMID:10588509 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:10588509 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
EXP ISO |
Epinephrine results in decreased expression of IL6 mRNA Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:10588509 PMID:12423672 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions decreases expression |
ISO |
[Epinephrine co-treated with INS protein] results in increased phosphorylation of AKT1 protein; Butoxamine inhibits the reaction [Epinephrine results in decreased expression of INS protein]; Pentolinium Tartrate inhibits the reaction [Epinephrine results in decreased secretion of INS protein]; Propranolol inhibits the reaction [Epinephrine results in decreased expression of INS protein] |
CTD |
PMID:1218171 PMID:6018752 PMID:6314140 PMID:32305330 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Epinephrine] |
CTD |
PMID:16214444 |
|
NCBI chr 2:46,996,904...47,097,011
Ensembl chr 2:47,000,323...47,096,961
|
|
G |
Itgav |
integrin subunit alpha V |
increases expression |
ISO |
Epinephrine results in increased expression of ITGAV mRNA |
CTD |
PMID:12729923 |
|
NCBI chr 3:71,113,269...71,205,958
Ensembl chr 3:71,114,100...71,202,411
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases response to substance |
EXP |
ITGB1 results in increased susceptibility to Epinephrine |
CTD |
PMID:14984413 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions increases expression affects localization increases activity |
ISO EXP |
Theophylline inhibits the reaction [Epinephrine results in increased activity of LIPE protein] Epinephrine results in increased expression of LIPE mRNA Epinephrine affects the localization of LIPE protein |
CTD |
PMID:7155675 PMID:10777495 PMID:11160373 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation increases activity affects activity |
ISO EXP |
ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; Epinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK1 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein] Epinephrine deficiency results in increased activity of MAPK1 protein Epinephrine affects the activity of MAPK1 protein |
CTD |
PMID:11093795 PMID:15292328 PMID:17680988 PMID:22496244 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation increases activity affects activity |
ISO EXP |
ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein] Epinephrine deficiency results in increased activity of MAPK3 protein Epinephrine affects the activity of MAPK3 protein |
CTD |
PMID:11093795 PMID:15292328 PMID:17680988 PMID:22496244 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Meis1 |
Meis homeobox 1 |
decreases expression |
ISO |
Epinephrine results in decreased expression of MEIS1 protein |
CTD |
PMID:31520687 |
|
NCBI chr14:103,182,178...103,321,809
Ensembl chr14:103,181,281...103,321,270
|
|
G |
Myl2 |
myosin light chain 2 |
multiple interactions affects expression |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] affects the expression of MYL2 protein Epinephrine affects the expression of MYL2 protein |
CTD |
PMID:19464573 |
|
NCBI chr12:39,951,863...39,959,065
Ensembl chr12:39,951,987...39,958,239
|
|
G |
Nefh |
neurofilament heavy chain |
affects expression |
EXP |
Epinephrine affects the expression of NEFH mRNA |
CTD |
PMID:22954530 |
|
NCBI chr14:85,181,572...85,191,557
Ensembl chr14:85,181,572...85,191,557
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine results in increased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:19135123 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Epinephrine results in increased expression of NOS2 mRNA |
CTD |
PMID:16925470 PMID:19439816 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Epinephrine results in increased expression of NTF3 mRNA; Epinephrine results in increased expression of NTF3 protein |
CTD |
PMID:19854260 |
|
NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases activity |
ISO |
Epinephrine results in decreased activity of P2RX7 protein |
CTD |
PMID:15459114 |
|
NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
multiple interactions |
ISO |
Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate] |
CTD |
PMID:11413167 |
|
NCBI chr 2:149,440,807...149,482,592
Ensembl chr 2:149,441,598...149,444,548
|
|
G |
Phb |
prohibitin |
multiple interactions increases expression |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of PHB protein Epinephrine results in increased expression of PHB protein |
CTD |
PMID:19464573 |
|
NCBI chr10:83,476,107...83,488,878
Ensembl chr10:83,476,107...83,488,878
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
increases expression |
EXP |
Epinephrine results in increased expression of PHGDH mRNA |
CTD |
PMID:12423672 |
|
NCBI chr 2:200,484,245...200,513,564
Ensembl chr 2:200,484,246...200,513,564
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PKM protein |
CTD |
PMID:19464573 |
|
NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
EXP |
Epinephrine results in increased expression of PPARGC1A mRNA |
CTD |
PMID:22496244 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
decreases expression multiple interactions |
EXP |
Epinephrine results in decreased expression of PPP2R1A protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PPP2R1A protein |
CTD |
PMID:19464573 |
|
NCBI chr 1:60,717,386...60,736,629
Ensembl chr 1:60,717,386...60,736,609
|
|
G |
Prdx6 |
peroxiredoxin 6 |
multiple interactions decreases expression |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PRDX6 protein Epinephrine results in decreased expression of PRDX6 protein |
CTD |
PMID:19464573 |
|
NCBI chr13:79,077,567...79,088,113
Ensembl chr13:79,077,033...79,088,127
|
|
G |
Prkce |
protein kinase C, epsilon |
affects response to substance |
ISO EXP |
PRKCE protein affects the susceptibility to Epinephrine |
CTD |
PMID:11454025 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Epinephrine results in decreased expression of PTGS2 mRNA; Epinephrine results in decreased expression of PTGS2 protein |
CTD |
PMID:31520687 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine results in increased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:19135123 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ren |
renin |
multiple interactions increases activity |
ISO |
ICI 118551 inhibits the reaction [Epinephrine results in increased activity of REN protein] |
CTD |
PMID:6314140 PMID:8592096 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Sct |
secretin |
multiple interactions |
EXP |
Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP] |
CTD |
PMID:6312992 |
|
NCBI chr 1:214,264,865...214,277,437
Ensembl chr 1:214,264,754...214,265,668
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
Epinephrine results in increased expression of SERPINE1 mRNA |
CTD |
PMID:15850565 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions increases uptake |
EXP ISO |
[Corticosterone results in decreased activity of SLC22A3 protein] inhibits the reaction [Epinephrine results in increased abundance of Epinephrine metabolite]; [Corticosterone results in decreased activity of SLC22A3 protein] which results in decreased abundance of Epinephrine SLC22A3 protein results in increased uptake of Epinephrine |
CTD |
PMID:19053318 PMID:20858707 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
increases uptake |
ISO |
SLC29A4 protein results in increased uptake of Epinephrine |
CTD |
PMID:20858707 |
|
NCBI chr12:13,914,114...13,924,511
Ensembl chr12:13,914,114...13,924,531
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions affects binding increases expression increases activity |
ISO EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]; Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Epinephrine results in increased activity of SOD1 protein] Epinephrine binds to SOD1 protein mutant form [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of SOD1 protein Epinephrine results in increased expression of SOD1 protein Epinephrine results in increased expression of SOD1 mRNA; Epinephrine results in increased expression of SOD1 protein |
CTD |
PMID:11163531 PMID:19464573 PMID:23612299 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression increases activity |
ISO EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]; Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]; Vitamin E inhibits the reaction [Epinephrine results in increased activity of SOD2 protein] [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of SOD2 protein Epinephrine results in increased expression of SOD2 protein Epinephrine results in increased expression of SOD2 mRNA; Epinephrine results in increased expression of SOD2 protein |
CTD |
PMID:11163531 PMID:19464573 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Suclg2 |
succinate-CoA ligase GDP-forming subunit beta |
increases expression |
EXP |
Epinephrine results in increased expression of SUCLG2 protein |
CTD |
PMID:19464573 |
|
NCBI chr 4:127,552,100...127,824,970
Ensembl chr 4:127,552,101...127,824,970
|
|
G |
Th |
tyrosine hydroxylase |
increases chemical synthesis multiple interactions |
ISO EXP |
TH protein results in increased chemical synthesis of Epinephrine [Clonidine results in increased expression of TH protein] which results in increased abundance of Epinephrine |
CTD |
PMID:9822156 PMID:19067675 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions decreases expression |
ISO |
Propranolol inhibits the reaction [Epinephrine results in decreased expression of THY1] |
CTD |
PMID:7558147 |
|
NCBI chr 8:48,382,121...48,387,271
Ensembl chr 8:48,382,121...48,386,935
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] Epinephrine results in decreased expression of TNF mRNA Epinephrine results in decreased secretion of TNF protein |
CTD |
PMID:10588509 PMID:12423672 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
increases expression multiple interactions |
EXP |
Epinephrine results in increased expression of VDAC1 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of VDAC1 protein |
CTD |
PMID:19464573 |
|
NCBI chr10:37,724,915...37,752,827
Ensembl chr10:37,724,915...37,752,826
|
|
G |
Wnt4 |
Wnt family member 4 |
decreases expression |
ISO |
Epinephrine results in decreased expression of WNT4 mRNA; Epinephrine results in decreased expression of WNT4 protein |
CTD |
PMID:31520687 |
|
NCBI chr 5:155,649,238...155,668,065
Ensembl chr 5:155,649,217...155,672,579
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
[Epinephrine co-treated with Xanthine co-treated with XDH] affects the expression of MYL2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of AK2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DES protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DLAT protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ECHS1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ETFB protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of FABP3 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HADH protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSP90AB1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPA9 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPB6 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of IDH2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PKM protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PPP2R1A protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PRDX6 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of SOD2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of C1QBP protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of CYCS protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of HSPA5 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of PHB protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of SOD1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of VDAC1 protein; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] affects the localization of HSF1 protein]; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of CASP3 protein] |
CTD |
PMID:19135123 PMID:19464573 |
|
NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
|
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
increases expression |
EXP |
Norepinephrine results in increased expression of ACTA1 mRNA |
CTD |
PMID:17592507 |
|
NCBI chr19:56,674,072...56,677,084
Ensembl chr19:56,674,074...56,677,084
|
|
G |
Ada |
adenosine deaminase |
multiple interactions decreases response to substance |
ISO EXP |
[ADA protein co-treated with Norepinephrine] results in increased secretion of Glycerol Propranolol promotes the reaction [ADA protein results in decreased susceptibility to Norepinephrine] |
CTD |
PMID:7949234 PMID:17428236 |
|
NCBI chr 3:160,115,840...160,139,947
Ensembl chr 3:160,115,842...160,139,947
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
affects binding multiple interactions increases activity affects expression affects response to substance |
ISO EXP |
Norepinephrine binds to ADRA1A protein [Norepinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1A protein; Norepinephrine inhibits the reaction [ADRA1A protein binds to Prazosin] Norepinephrine results in increased activity of ADRA1A protein 5-methylurapidil inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; [chlorethylclonidine co-treated with Phenoxybenzamine] inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; BMY 7378 inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; chlorethylclonidine inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Phenoxybenzamine inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Spiperone inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein] Norepinephrine affects the expression of ADRA1A protein ADRA1A protein affects the susceptibility to Norepinephrine |
CTD |
PMID:8183249 PMID:10416824 PMID:12417256 PMID:20030735 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
multiple interactions |
ISO |
[Norepinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1B protein; Norepinephrine inhibits the reaction [ADRA1B protein binds to Prazosin] |
CTD |
PMID:20030735 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
affects binding multiple interactions affects response to substance |
ISO EXP |
Norepinephrine binds to ADRA1D protein [Norepinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1D protein; Norepinephrine inhibits the reaction [ADRA1D protein binds to Prazosin] ADRA1D affects the susceptibility to Norepinephrine Norepinephrine binds to and affects the activity of ADRA1D protein |
CTD |
PMID:8183249 PMID:9639061 PMID:11901185 PMID:15493479 PMID:20030735 |
|
NCBI chr 3:124,129,558...124,145,566
Ensembl chr 3:124,129,558...124,145,566
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
affects secretion multiple interactions affects abundance affects binding |
EXP ISO |
ADRA2A protein affects the secretion of Norepinephrine [ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine ADRA2A protein affects the abundance of Norepinephrine 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; [Norepinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; Brimonidine Tartrate inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Dexmedetomidine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Norepinephrine binds to and results in increased activity of ADRA2A protein; Norepinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]; Prazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; talipexole inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Thapsigargin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Yohimbine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein] Norepinephrine binds to ADRA2A protein [BRL 44408 binds to and results in decreased activity of ADRA2A protein] inhibits the reaction [Xylazine inhibits the reaction [Potassium results in increased secretion of Norepinephrine]] |
CTD |
PMID:10336518 PMID:10742289 PMID:11312645 PMID:20030735 PMID:20083574 |
|
NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
|
|
G |
Adra2b |
adrenoceptor alpha 2B |
multiple interactions |
ISO |
[Norepinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA2B protein; Norepinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan] |
CTD |
PMID:20030735 |
|
NCBI chr 3:119,805,941...119,809,987
Ensembl chr 3:119,805,941...119,809,987
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
affects binding multiple interactions |
ISO |
Norepinephrine binds to ADRA2C protein [ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine [Norepinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA2C protein; Norepinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan] |
CTD |
PMID:10336518 PMID:20030735 PMID:20083574 |
|
NCBI chr14:80,730,307...80,732,010
Ensembl chr14:80,730,307...80,732,010
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO EXP |
[Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB1 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Norepinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Norepinephrine promotes the reaction [ADRB1 protein results in increased activity of GNAS protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB1 protein]; Propranolol inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRB1 protein] [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased activity of Norepinephrine |
CTD |
PMID:8096834 PMID:10344530 PMID:12010770 PMID:14730417 PMID:17200720 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions affects binding |
EXP ISO |
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Fenoterol affects the abundance of Norepinephrine] [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB2 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB2 protein]; Propranolol inhibits the reaction [Norepinephrine binds to ADRB2 protein]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine binds to ADRB2 protein] |
CTD |
PMID:7969507 PMID:10344530 PMID:14730417 PMID:24929186 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions increases activity |
ISO EXP |
[Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB3 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB3 protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB3 protein] Norepinephrine results in increased activity of ADRB3 protein 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [Norepinephrine results in increased activity of ADRB3 protein]; Norepinephrine binds to and results in increased activity of ADRB3 protein |
CTD |
PMID:1682311 PMID:7815362 PMID:8569714 PMID:10344530 PMID:14730417 PMID:17622774 |
|
NCBI chr16:69,003,541...69,006,632
Ensembl chr16:69,003,868...69,006,632
|
|
G |
Agt |
angiotensinogen |
increases abundance affects abundance multiple interactions |
EXP |
AGT protein results in increased abundance of Norepinephrine Norepinephrine affects the abundance of AGT protein carvedilol inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]; Losartan inhibits the reaction [AGT protein results in increased abundance of Norepinephrine] |
CTD |
PMID:614752 PMID:15741261 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
affects response to substance |
ISO |
AGTR2 protein affects the susceptibility to Norepinephrine |
CTD |
PMID:11714657 |
|
NCBI chr X:119,389,480...119,393,845
Ensembl chr X:119,390,013...119,393,842
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
EXP |
Norepinephrine results in decreased expression of AKT1 protein modified form |
CTD |
PMID:16338971 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
ANXA1 affects the reaction [Norepinephrine results in decreased secretion of IL6 protein] |
CTD |
PMID:16835395 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Aqp2 |
aquaporin 2 |
decreases expression |
EXP |
Norepinephrine results in decreased expression of AQP2 protein |
CTD |
PMID:16788141 |
|
NCBI chr 7:141,237,802...141,242,837
Ensembl chr 7:141,237,768...141,245,165
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
affects abundance decreases expression |
ISO EXP |
ATP2A2 protein affects the abundance of Norepinephrine Norepinephrine results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:17592507 PMID:19328205 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA |
CTD |
PMID:11742803 |
|
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP |
N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of BAX protein] Norepinephrine results in increased expression of BAX mRNA; Norepinephrine results in increased expression of BAX protein |
CTD |
PMID:18675472 PMID:20374255 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein] |
CTD |
PMID:14732211 PMID:17041759 PMID:20374255 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
EXP |
Norepinephrine results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:18675472 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects response to substance |
ISO |
BDKRB2 affects the susceptibility to Norepinephrine |
CTD |
PMID:12105144 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
C5ar2 |
complement component 5a receptor 2 |
increases expression |
EXP |
Norepinephrine results in increased expression of C5AR2 mRNA; Norepinephrine results in increased expression of C5AR2 protein |
CTD |
PMID:15715664 |
|
NCBI chr 1:78,165,155...78,183,426
Ensembl chr 1:78,166,810...78,180,216
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
affects response to substance increases abundance multiple interactions |
EXP |
CALCA protein affects the susceptibility to Norepinephrine CALCA protein results in increased abundance of Norepinephrine Propranolol promotes the reaction [CALCA protein affects the susceptibility to Norepinephrine] |
CTD |
PMID:8058111 PMID:18055875 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Caly |
calcyon neuron-specific vesicular protein |
increases secretion |
ISO |
CALY protein results in increased secretion of Norepinephrine |
CTD |
PMID:30753204 |
|
NCBI chr 1:212,537,851...212,549,040
Ensembl chr 1:212,537,848...212,549,477
|
|
G |
Casp12 |
caspase 12 |
multiple interactions increases cleavage |
EXP |
CAT protein inhibits the reaction [Norepinephrine results in increased cleavage of CASP12 protein alternative form] |
CTD |
PMID:16338971 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp2 |
caspase 2 |
multiple interactions increases activity |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein] |
CTD |
PMID:14732211 PMID:15158148 PMID:17041759 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
ISO EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of and results in increased cleavage of CASP3 protein]; Norepinephrine results in increased activity of and results in increased cleavage of CASP3 protein Norepinephrine results in increased activity of CASP3 protein Norepinephrine results in increased cleavage of CASP3 protein Norepinephrine results in increased expression of CASP3 protein Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of CASP3 protein]; Norepinephrine inhibits the reaction [Okadaic Acid results in increased activity of CASP3 protein] |
CTD |
PMID:11099166 PMID:14732211 PMID:15158148 PMID:16338971 PMID:17041759 PMID:17136323 PMID:18675472 PMID:20374255 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp6 |
caspase 6 |
multiple interactions increases activity |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein] |
CTD |
PMID:14732211 PMID:15158148 |
|
NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967 Ensembl chr 2:235,341,365...235,353,967
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of and results in increased cleavage of CASP7 protein]; Norepinephrine results in increased activity of and results in increased cleavage of CASP7 protein |
CTD |
PMID:17136323 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
affects activity |
EXP |
Norepinephrine affects the activity of CASP8 protein |
CTD |
PMID:25437044 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions affects activity increases cleavage increases activity |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein] Norepinephrine affects the activity of CASP9 protein Norepinephrine results in increased cleavage of CASP9 protein |
CTD |
PMID:14732211 PMID:15158148 PMID:16338971 PMID:25437044 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [Norepinephrine results in increased cleavage of CASP12 protein alternative form] |
CTD |
PMID:16338971 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Norepinephrine inhibits the reaction [Thioglycolates results in increased secretion of CCL3 protein]; Propranolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]] |
CTD |
PMID:9863660 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases secretion multiple interactions |
ISO |
Norepinephrine results in increased secretion of CCL5 protein Prazosin inhibits the reaction [Norepinephrine results in increased secretion of CCL5 protein] |
CTD |
PMID:16782692 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
Norepinephrine results in increased expression of CCN1 mRNA |
CTD |
PMID:15117851 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects expression |
ISO |
Norepinephrine affects the expression of CNR1 mRNA |
CTD |
PMID:29650773 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
EXP |
carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]; Doxazosin inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:10722803 PMID:14577597 PMID:19575289 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression multiple interactions |
EXP |
Norepinephrine results in increased expression of COL3A1 mRNA carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA] |
CTD |
PMID:10722803 PMID:14577597 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions increases methylation |
ISO |
[tolcapone results in decreased activity of COMT protein] which results in increased abundance of Norepinephrine COMT protein results in increased methylation of Norepinephrine |
CTD |
PMID:11160877 PMID:11248589 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
EXP |
Norepinephrine results in decreased expression of CPT1A mRNA |
CTD |
PMID:19109942 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Crem |
cAMP responsive element modulator |
increases expression |
ISO |
Norepinephrine results in increased expression of CREM mRNA |
CTD |
PMID:11171092 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions increases abundance |
EXP |
corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein affects the abundance of Norepinephrine]; Norepinephrine affects the expression of and affects the secretion of CRH protein; Propranolol affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein]; Yohimbine affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein] CRH results in increased abundance of Norepinephrine |
CTD |
PMID:1320258 PMID:3497798 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
EXP |
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency affects the abundance of Norepinephrine]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone affects the abundance of Norepinephrine] |
CTD |
PMID:24398105 |
|
NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization increases localization |
EXP |
Norepinephrine affects the localization of CYCS protein Norepinephrine results in increased localization of CYCS protein |
CTD |
PMID:16338971 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Dbh |
dopamine beta-hydroxylase |
affects abundance increases abundance decreases abundance |
ISO |
DBH gene polymorphism affects the abundance of Norepinephrine DBH protein results in increased abundance of Norepinephrine DBH mutant form results in decreased abundance of Norepinephrine |
CTD |
PMID:15148402 PMID:16163519 PMID:18329701 |
|
NCBI chr 3:5,709,236...5,731,895
Ensembl chr 3:5,709,236...5,731,898
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP |
Norepinephrine results in increased expression of DDIT3 mRNA; Norepinephrine results in increased expression of DDIT3 protein |
CTD |
PMID:16338971 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
Norepinephrine inhibits the reaction [Rotenone results in decreased expression of DRD1 mRNA]; Norepinephrine inhibits the reaction [Rotenone results in decreased expression of DRD1 protein] |
CTD |
PMID:20887679 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO EXP |
[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium; Sulpiride inhibits the reaction [[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium] Norepinephrine inhibits the reaction [Rotenone results in increased expression of DRD2 mRNA]; Norepinephrine inhibits the reaction [Rotenone results in increased expression of DRD2 protein] |
CTD |
PMID:8032591 PMID:20887679 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases expression increases activity decreases secretion increases secretion |
EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; [EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; BQ 610 inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; KT 5823 inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of EDN1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; Picrotoxin inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine] Norepinephrine results in increased activity of EDN1 promoter |
CTD |
PMID:11435416 PMID:12184995 PMID:14759557 PMID:16023617 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions decreases secretion increases secretion |
EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; 2-aminoethoxydiphenyl borate inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; bisindolylmaleimide I inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]; KT 5823 inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]; Picrotoxin inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine] |
CTD |
PMID:12184995 PMID:14759557 PMID:16023617 |
|
NCBI chr 3:172,856,730...172,879,276
Ensembl chr 3:172,856,733...172,880,450
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
[cyclo(Trp-Asp-Pro-Val-Leu) binds to and results in decreased activity of EDNRA protein] which results in decreased susceptibility to Norepinephrine |
CTD |
PMID:15834289 |
|
NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine |
CTD |
PMID:16023617 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Efhd2 |
EF-hand domain family, member D2 |
increases secretion |
ISO |
EFHD2 gene mutant form results in increased secretion of Norepinephrine |
CTD |
PMID:28397836 |
|
NCBI chr 5:160,407,777...160,423,811
Ensembl chr 5:160,407,778...160,423,811
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [EGF protein co-treated with Norepinephrine] results in increased expression of MYC mRNA |
CTD |
PMID:11742803 PMID:12632255 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
EGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form] |
CTD |
PMID:19168439 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
EXP |
Norepinephrine results in increased expression of EGR1 |
CTD |
PMID:7905536 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
EXP |
[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:11880281 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
multiple interactions increases expression |
ISO |
[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA; Dactinomycin inhibits the reaction [Norepinephrine results in increased expression of ELOVL3 mRNA]; Norepinephrine results in increased expression of and results in decreased degradation of ELOVL3 mRNA; rosiglitazone promotes the reaction [[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA] |
CTD |
PMID:17726147 |
|
NCBI chr 1:265,883,353...265,887,181
Ensembl chr 1:265,883,355...265,887,226
|
|
G |
Epo |
erythropoietin |
decreases response to substance |
ISO |
EPO protein results in decreased susceptibility to Norepinephrine |
CTD |
PMID:14732207 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Norepinephrine promotes the reaction [REL protein binds to F3 promoter]; Norepinephrine promotes the reaction [RELA protein binds to F3 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA] |
CTD |
PMID:23114885 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; KT 5720 inhibits the reaction [Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]]; Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein] |
CTD |
PMID:11742803 PMID:15264218 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]] |
CTD |
PMID:11742803 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Norepinephrine co-treated with Prazosin] results in decreased expression of FN1 protein; [Norepinephrine co-treated with Propranolol] results in increased expression of FN1 protein |
CTD |
PMID:11821714 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fndc5 |
fibronectin type III domain containing 5 |
decreases abundance |
EXP |
FNDC5 protein results in decreased abundance of Norepinephrine |
CTD |
PMID:32165127 |
|
NCBI chr 5:147,323,240...147,330,266
Ensembl chr 5:147,323,240...147,330,266
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO EXP |
Norepinephrine results in increased expression of FOS mRNA Norepinephrine results in increased expression of FOS; Norepinephrine results in increased expression of FOS mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Norepinephrine results in increased expression of FOS mRNA] |
CTD |
PMID:7605896 PMID:7905536 PMID:12729908 PMID:19225867 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Norepinephrine results in increased expression of FOSB |
CTD |
PMID:7905536 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]; SHC1 protein affects the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:19168439 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity multiple interactions increases expression |
EXP |
Norepinephrine results in increased activity of G6PD mRNA; Norepinephrine results in increased activity of G6PD protein Metoprolol inhibits the reaction [Norepinephrine results in increased activity of G6PD protein]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of G6PD protein] Norepinephrine results in increased expression of G6PD mRNA |
CTD |
PMID:1378361 PMID:7605896 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gabpa |
GA binding protein transcription factor subunit alpha |
multiple interactions |
EXP |
[Progesterone co-treated with Norepinephrine] results in increased expression of GABPA mRNA |
CTD |
PMID:16954335 |
|
NCBI chr11:24,293,845...24,322,822
Ensembl chr11:24,263,281...24,322,815
|
|
G |
Gk |
glycerol kinase |
increases activity increases expression |
EXP |
Norepinephrine results in increased activity of GK protein Norepinephrine results in increased expression of GK mRNA |
CTD |
PMID:12736183 |
|
NCBI chr X:54,227,291...54,303,897
Ensembl chr X:54,227,397...54,303,864
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
Norepinephrine promotes the reaction [ADRB1 protein results in increased activity of GNAS protein] |
CTD |
PMID:17200720 |
|
NCBI chr 3:172,374,957...172,434,988
Ensembl chr 3:172,374,957...172,428,483 Ensembl chr 3:172,374,957...172,428,483
|
|
G |
Hdc |
histidine decarboxylase |
affects abundance |
ISO |
HDC protein affects the abundance of Norepinephrine |
CTD |
PMID:12421355 |
|
NCBI chr 3:119,057,524...119,075,599
Ensembl chr 3:119,057,517...119,075,619
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Propranolol inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA] |
CTD |
PMID:24929186 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Norepinephrine results in increased expression of HSPA5 mRNA; Norepinephrine results in increased expression of HSPA5 protein |
CTD |
PMID:16338971 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Htr2b |
5-hydroxytryptamine receptor 2B |
multiple interactions increases expression |
EXP |
N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of HTR2B protein] |
CTD |
PMID:20374255 |
|
NCBI chr 9:93,112,781...93,130,135
Ensembl chr 9:93,112,805...93,125,014
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]]; Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]; Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]; Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; wortmannin inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]] |
CTD |
PMID:23114885 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions decreases response to substance |
EXP |
Prazosin inhibits the reaction [IGF1 protein results in decreased susceptibility to Norepinephrine] |
CTD |
PMID:17184500 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il1b |
interleukin 1 beta |
affects secretion increases expression multiple interactions |
EXP |
Norepinephrine affects the secretion of IL1B protein Norepinephrine results in increased expression of IL1B mRNA carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL1B mRNA]; Norepinephrine promotes the reaction [IL1B protein results in increased expression of IL6 protein] |
CTD |
PMID:8392517 PMID:10722803 PMID:16386803 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression increases activity decreases secretion |
ISO EXP |
Norepinephrine results in increased expression of and results in increased secretion of IL6 protein; sulforaphane inhibits the reaction [Norepinephrine results in increased expression of and results in increased secretion of IL6 protein] Norepinephrine results in increased expression of IL6 mRNA; Norepinephrine results in increased expression of IL6 protein Norepinephrine results in increased activity of IL6 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; ICI 118551 inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Norepinephrine promotes the reaction [IL1B protein results in increased expression of IL6 protein]; Norepinephrine promotes the reaction [TNF protein results in increased expression of IL6 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA] Norepinephrine results in decreased secretion of IL6 protein ANXA1 affects the reaction [Norepinephrine results in decreased secretion of IL6 protein] |
CTD |
PMID:8392517 PMID:10722803 PMID:11406463 PMID:12619890 PMID:14577597 PMID:16835395 PMID:18636164 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases phosphorylation increases expression |
EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Norepinephrine results in increased expression of JUN mRNA] Norepinephrine results in increased expression of JUN; Norepinephrine results in increased expression of JUN mRNA |
CTD |
PMID:7905536 PMID:19225867 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Norepinephrine results in increased expression of JUNB |
CTD |
PMID:7905536 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
affects response to substance |
EXP |
KCNMA1 protein affects the susceptibility to Norepinephrine |
CTD |
PMID:22226998 |
|
NCBI chr15:344,204...1,048,849
Ensembl chr15:344,360...1,047,956
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein; Phenoxybenzamine inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]; Piperoxan inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]; Prazosin inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein] |
CTD |
PMID:3953791 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions increases expression |
EXP |
Prazosin inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA] |
CTD |
PMID:9032464 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Maoa |
monoamine oxidase A |
increases metabolic processing increases abundance |
ISO |
MAOA protein results in increased metabolism of Norepinephrine MAOA mutant form results in increased abundance of Norepinephrine |
CTD |
PMID:10647887 PMID:11834493 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Maob |
monoamine oxidase B |
increases abundance |
ISO |
MAOB mutant form results in increased abundance of Norepinephrine |
CTD |
PMID:11834493 |
|
NCBI chr X:6,430,694...6,533,520
Ensembl chr X:6,430,594...6,533,534
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Norepinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK1 protein] Norepinephrine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]; AG 1879 inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; [Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK1 protein]; Cadmium Chloride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; cadmium sulfate inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]; diphenyleneiodonium inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein; oxophenylarsine inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Prazosin affects the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:10788502 PMID:11054474 PMID:11880281 PMID:11914123 PMID:15292328 PMID:17041759 PMID:20434527 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk10 |
mitogen activated protein kinase 10 |
multiple interactions |
ISO |
MAPK10 protein affects the reaction [MAPK9 protein affects the susceptibility to Norepinephrine] |
CTD |
PMID:16949803 |
|
NCBI chr14:8,079,955...8,371,508
Ensembl chr14:8,080,275...8,368,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
Norepinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; [Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK3 protein]; Cadmium Chloride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; cadmium sulfate inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK3 protein; oxophenylarsine inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:10788502 PMID:11054474 PMID:11880281 PMID:11914123 PMID:15292328 PMID:17041759 PMID:20434527 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:17041759 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions affects response to substance |
ISO |
MAPK10 protein affects the reaction [MAPK9 protein affects the susceptibility to Norepinephrine] |
CTD |
PMID:16949803 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression increases activity |
EXP ISO |
Cromolyn Sodium inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; Norepinephrine results in increased activity of and results in increased expression of MMP2 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased activity of MMP2 protein]; trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA] Propranolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA] |
CTD |
PMID:14577597 PMID:15326086 PMID:16864425 PMID:24929186 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression increases activity |
EXP ISO |
trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA] Norepinephrine results in increased activity of MMP9 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; Propranolol inhibits the reaction [Norepinephrine results in increased activity of MMP9 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased activity of MMP9 protein]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; SR 11302 inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; tanshinone inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA] |
CTD |
PMID:16864425 PMID:24929186 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression |
EXP |
[EGF protein co-treated with Norepinephrine] results in increased expression of MYC mRNA Norepinephrine results in increased expression of MYC |
CTD |
PMID:7605896 PMID:12632255 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myh6 |
myosin heavy chain 6 |
decreases expression |
EXP |
Norepinephrine results in decreased expression of MYH6 mRNA |
CTD |
PMID:17592507 |
|
NCBI chr15:33,605,653...33,629,730
Ensembl chr15:33,605,654...33,629,699
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions affects expression increases expression |
EXP |
Propranolol promotes the reaction [Norepinephrine results in increased expression of MYH7 mRNA] Norepinephrine affects the expression of MYH7 mRNA |
CTD |
PMID:17592507 PMID:25437044 |
|
NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
increases expression |
ISO |
Norepinephrine results in increased expression of NFIL3 mRNA |
CTD |
PMID:12729908 |
|
NCBI chr17:12,261,102...12,276,316
Ensembl chr17:12,261,102...12,276,315
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions affects localization |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Norepinephrine affects the localization of [NFKB1 protein binds to RELA protein]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]; Norepinephrine results in increased activity of [NFKB1 protein binds to RELA protein]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein] |
CTD |
PMID:16782692 PMID:23114885 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Ngf |
nerve growth factor |
decreases expression |
EXP |
Norepinephrine results in decreased expression of NGF mRNA; Norepinephrine results in decreased expression of NGF protein |
CTD |
PMID:8593794 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions affects response to substance |
ISO |
[GW 274150 results in decreased activity of NOS2 protein] which results in increased susceptibility to Norepinephrine; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] NOS2 protein affects the susceptibility to Norepinephrine |
CTD |
PMID:16424707 PMID:19439816 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nppa |
natriuretic peptide A |
increases expression multiple interactions |
ISO EXP |
Norepinephrine results in increased expression of NPPA mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Carvedilol inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Propranolol promotes the reaction [Norepinephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:9788975 PMID:10722803 PMID:14577597 PMID:15240149 PMID:16714034 PMID:17266992 PMID:17592507 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nppb |
natriuretic peptide B |
affects abundance decreases abundance |
ISO |
NPPB affects the abundance of Norepinephrine NPPB protein results in decreased abundance of Norepinephrine |
CTD |
PMID:16333235 PMID:20339970 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Npy |
neuropeptide Y |
affects response to substance |
ISO |
NPY protein affects the susceptibility to Norepinephrine |
CTD |
PMID:15003356 |
|
NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097 Ensembl chr 4:79,557,854...79,565,097
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions |
EXP |
[Estradiol co-treated with Norepinephrine] results in decreased expression of NRF1 mRNA |
CTD |
PMID:16954335 |
|
NCBI chr 4:57,335,732...57,445,317
Ensembl chr 4:57,378,069...57,445,341
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Norepinephrine results in increased expression of NTF3 mRNA; Norepinephrine results in increased expression of NTF3 protein |
CTD |
PMID:19854260 |
|
NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases activity |
EXP |
Norepinephrine results in decreased activity of ODC1 protein |
CTD |
PMID:1850525 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
multiple interactions |
EXP |
[dextrallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine |
CTD |
PMID:7562497 |
|
NCBI chr 5:150,288,126...150,323,063
Ensembl chr 5:150,288,126...150,323,063
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
multiple interactions |
EXP |
[dextrallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine |
CTD |
PMID:7562497 |
|
NCBI chr 5:13,742,655...13,760,460
Ensembl chr 5:13,744,658...13,760,305
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
EXP |
[dextrallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine |
CTD |
PMID:7562497 |
|
NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
|
|
G |
Per1 |
period circadian regulator 1 |
increases expression |
ISO |
Norepinephrine results in increased expression of PER1 mRNA |
CTD |
PMID:12729908 |
|
NCBI chr10:55,681,761...55,696,557
Ensembl chr10:55,687,050...55,695,994
|
|
G |
Per2 |
period circadian regulator 2 |
increases expression |
ISO |
Norepinephrine results in increased expression of PER2 mRNA |
CTD |
PMID:12729908 |
|
NCBI chr 9:98,555,154...98,597,362
Ensembl chr 9:98,555,169...98,597,359
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
multiple interactions increases activity |
EXP |
carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD protein] |
CTD |
PMID:1378361 |
|
NCBI chr 5:165,966,128...165,982,327
|
|
G |
Plcb1 |
phospholipase C beta 1 |
increases activity multiple interactions increases expression |
EXP |
Norepinephrine results in increased activity of PLCB1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA] Norepinephrine results in increased expression of PLCB1 mRNA; Norepinephrine results in increased expression of PLCB1 protein |
CTD |
PMID:16714034 PMID:19225867 |
|
NCBI chr 3:127,721,244...128,419,565
Ensembl chr 3:128,155,069...128,419,545
|
|
G |
Plcb3 |
phospholipase C beta 3 |
increases activity multiple interactions increases expression |
EXP |
Norepinephrine results in increased activity of PLCB3 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA] Norepinephrine results in increased expression of PLCB3 mRNA; Norepinephrine results in increased expression of PLCB3 protein |
CTD |
PMID:16714034 PMID:19225867 |
|
NCBI chr 1:222,207,887...222,224,993
Ensembl chr 1:222,209,575...222,224,910
|
|
G |
Plcd1 |
phospholipase C, delta 1 |
increases activity multiple interactions increases expression |
EXP |
Norepinephrine results in increased activity of PLCD1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA] Norepinephrine results in increased expression of PLCD1 mRNA; Norepinephrine results in increased expression of PLCD1 protein |
CTD |
PMID:16714034 PMID:19225867 |
|
NCBI chr 8:127,753,514...127,782,070
Ensembl chr 8:127,753,539...127,782,070
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
increases activity multiple interactions increases expression |
EXP |
Norepinephrine results in increased activity of PLCG1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein] Norepinephrine results in increased expression of PLCG1 mRNA; Norepinephrine results in increased expression of PLCG1 protein |
CTD |
PMID:16714034 PMID:19225867 |
|
NCBI chr 3:156,727,642...156,758,307
Ensembl chr 3:156,727,642...156,758,307
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
Norepinephrine results in increased expression of PPARA mRNA |
CTD |
PMID:19109942 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
Norepinephrine results in increased expression of PPARG mRNA |
CTD |
PMID:19109942 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO EXP |
[Propranolol co-treated with Prazosin] inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA] Norepinephrine inhibits the reaction [Testosterone results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:16513826 PMID:16954335 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
EXP |
[Estradiol co-treated with Norepinephrine] results in decreased expression of PTEN mRNA; [Progesterone co-treated with Norepinephrine] results in increased expression of PTEN mRNA; Norepinephrine inhibits the reaction [Testosterone results in decreased expression of PTEN mRNA] |
CTD |
PMID:16954335 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Norepinephrine |
CTD |
PMID:15834289 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO |
Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of REL protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of REL protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]; Norepinephrine promotes the reaction [REL protein binds to F3 promoter]; Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of REL protein]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of REL protein]; wortmannin inhibits the reaction [Norepinephrine affects the localization of REL protein]; wortmannin inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]] |
CTD |
PMID:23114885 |
|
NCBI chr14:108,490,794...108,517,582
Ensembl chr14:108,491,069...108,509,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine affects the localization of RELA protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]]; Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of RELA protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of RELA protein]; Norepinephrine affects the localization of [NFKB1 protein binds to RELA protein]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; Norepinephrine promotes the reaction [RELA protein binds to F3 promoter]; Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]; Norepinephrine results in increased activity of [NFKB1 protein binds to RELA protein]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of RELA protein]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of RELA protein] |
CTD |
PMID:16782692 PMID:23114885 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
ISO |
Norepinephrine results in increased expression of S100A8 mRNA; Norepinephrine results in increased expression of S100A8 protein |
CTD |
PMID:16677282 |
|
NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Norepinephrine results in increased expression of S100A9 mRNA; Norepinephrine results in increased expression of S100A9 protein |
CTD |
PMID:16677282 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
S100b |
S100 calcium binding protein B |
increases expression affects response to substance |
ISO |
Norepinephrine results in increased expression of S100B mRNA; Norepinephrine results in increased expression of S100B protein S100B protein affects the susceptibility to Norepinephrine |
CTD |
PMID:9788975 |
|
NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
EXP |
Norepinephrine results in increased expression of SCD1 mRNA |
CTD |
PMID:22413010 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
Norepinephrine results in increased expression of SERPINE1 mRNA |
CTD |
PMID:17429342 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Serpinh1 |
serpin family H member 1 |
multiple interactions increases expression |
EXP |
carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 protein] Norepinephrine results in increased expression of SERPINH1 mRNA; Norepinephrine results in increased expression of SERPINH1 protein |
CTD |
PMID:10722803 |
|
NCBI chr 1:164,301,010...164,308,306
Ensembl chr 1:164,301,010...164,308,317
|
|
G |
Shc1 |
SHC adaptor protein 1 |
multiple interactions increases phosphorylation |
EXP |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; EGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; Prazosin inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; SHC1 protein affects the reaction [Norepinephrine results in decreased expression of SOD2 protein]; SHC1 protein affects the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; U 0126 inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form] |
CTD |
PMID:19168439 |
|
NCBI chr 2:188,745,503...188,757,066
Ensembl chr 2:188,745,503...188,757,066
|
|
G |
Slc12a1 |
solute carrier family 12 member 1 |
decreases expression |
EXP |
Norepinephrine results in decreased expression of SLC12A1 protein |
CTD |
PMID:16788141 |
|
NCBI chr 3:117,421,531...117,498,372
Ensembl chr 3:117,421,604...117,498,367
|
|
G |
Slc14a2 |
solute carrier family 14 member 2 |
decreases expression |
EXP |
Norepinephrine results in decreased expression of SLC14A2 protein |
CTD |
PMID:16788141 |
|
NCBI chr18:74,508,070...74,941,389
Ensembl chr18:74,546,220...74,688,551 Ensembl chr18:74,546,220...74,688,551
|
|
G |
Slc18a1 |
solute carrier family 18 member A1 |
multiple interactions |
ISO |
Norepinephrine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin] |
CTD |
PMID:8245983 |
|
NCBI chr16:22,358,646...22,395,183
Ensembl chr16:22,361,998...22,395,183
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions decreases activity affects binding |
EXP ISO |
Norepinephrine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin] Norepinephrine results in decreased activity of SLC18A2 protein Norepinephrine binds to SLC18A2 protein |
CTD |
PMID:1438304 PMID:7912402 PMID:15475732 |
|
NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
increases uptake multiple interactions |
ISO EXP |
SLC22A3 protein results in increased uptake of Norepinephrine Norepinephrine affects the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:9830022 PMID:20858707 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
increases uptake |
ISO |
SLC29A4 protein results in increased uptake of Norepinephrine |
CTD |
PMID:20858707 |
|
NCBI chr12:13,914,114...13,924,511
Ensembl chr12:13,914,114...13,924,531
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions increases uptake decreases expression decreases uptake decreases activity |
ISO EXP |
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A2 protein results in increased uptake of Norepinephrine]; Norepinephrine inhibits the reaction [nisoxetine binds to SLC6A2 protein]; SLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] Norepinephrine affects the localization of and affects the metabolism of SLC6A2 protein [Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine; Bupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]; Lidocaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]; tricaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine] Norepinephrine results in decreased expression of SLC6A2 protein SLC6A2 mutant form results in decreased uptake of Norepinephrine Norepinephrine results in decreased activity of SLC6A2 protein |
CTD |
PMID:11082428 PMID:11458707 PMID:16338971 PMID:16725121 PMID:17234900 PMID:30776375 |
|
NCBI chr19:15,391,682...15,431,274
Ensembl chr19:15,391,581...15,431,274
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions increases uptake |
ISO |
SLC6A3 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] SLC6A3 protein results in increased uptake of Norepinephrine |
CTD |
PMID:17234900 PMID:17250655 |
|
NCBI chr 1:32,323,011...32,363,983
Ensembl chr 1:32,321,580...32,363,983
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions |
ISO |
SLC6A4 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr10:63,153,656...63,188,377
Ensembl chr10:63,153,651...63,176,463
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
increases expression |
EXP |
Norepinephrine results in increased expression of SLC8A1 mRNA; Norepinephrine results in increased expression of SLC8A1 protein |
CTD |
PMID:11179087 |
|
NCBI chr 6:4,244,076...4,564,262
Ensembl chr 6:4,258,991...4,520,604
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression increases expression multiple interactions |
EXP ISO |
Norepinephrine results in decreased expression of SOD2 protein Norepinephrine results in increased expression of SOD2 mRNA Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA] SHC1 protein affects the reaction [Norepinephrine results in decreased expression of SOD2 protein] |
CTD |
PMID:19168439 PMID:23114885 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Taar1 |
trace-amine-associated receptor 1 |
multiple interactions |
ISO |
SLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] |
CTD |
PMID:17234900 |
|
NCBI chr 1:22,595,477...22,596,475
Ensembl chr 1:22,595,477...22,596,475
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions |
EXP |
[SQ 29548 binds to and results in decreased activity of TBXA2R protein] which results in decreased susceptibility to Norepinephrine |
CTD |
PMID:15834289 |
|
NCBI chr 7:11,253,153...11,259,233
Ensembl chr 7:11,253,180...11,257,977
|
|
G |
Tfam |
transcription factor A, mitochondrial |
multiple interactions |
EXP |
[Estradiol co-treated with Norepinephrine] results in decreased expression of TFAM mRNA; [Progesterone co-treated with Norepinephrine] results in increased expression of TFAM mRNA |
CTD |
PMID:16954335 |
|
NCBI chr20:18,594,057...18,606,106
Ensembl chr20:18,594,037...18,606,151
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
EXP |
Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB1 mRNA] |
CTD |
PMID:15326086 PMID:19575289 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression multiple interactions |
EXP |
Norepinephrine results in increased expression of TGFB2 mRNA; Norepinephrine results in increased expression of TGFB2 protein Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB2 mRNA] |
CTD |
PMID:15326086 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
increases expression multiple interactions |
EXP |
Norepinephrine results in increased expression of TGFB3 mRNA Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB3 mRNA] |
CTD |
PMID:15326086 |
|
NCBI chr 6:109,913,757...109,936,217
Ensembl chr 6:109,913,757...109,935,533
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions increases chemical synthesis |
EXP ISO |
[Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Norepinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Norepinephrine TH protein results in increased chemical synthesis of Norepinephrine |
CTD |
PMID:9822156 PMID:19067675 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
decreases expression multiple interactions |
ISO |
Norepinephrine results in decreased expression of THY1 Propranolol inhibits the reaction [Norepinephrine results in decreased expression of THY1] |
CTD |
PMID:7558147 |
|
NCBI chr 8:48,382,121...48,387,271
Ensembl chr 8:48,382,121...48,386,935
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions increases expression |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA] |
CTD |
PMID:14577597 PMID:15326086 |
|
NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
EXP |
Acetylcysteine inhibits the reaction [Norepinephrine results in increased secretion of TNF protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased secretion of TNF protein]; Norepinephrine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; Norepinephrine promotes the reaction [TNF protein results in increased expression of IL6 protein] Norepinephrine results in increased expression of TNF mRNA |
CTD |
PMID:8392517 PMID:15081246 PMID:15158148 PMID:25437044 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 Ensembl chr20:5,189,390...5,192,000
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions increases expression |
ISO EXP |
[Rosiglitazone results in increased susceptibility to Norepinephrine] which results in increased expression of UCP1 mRNA; [Rosiglitazone results in increased susceptibility to Norepinephrine] which results in increased expression of UCP1 protein; AG 1879 promotes the reaction [Norepinephrine results in increased expression of UCP1 mRNA] [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA |
CTD |
PMID:10465291 PMID:10788502 PMID:11742803 PMID:29910772 PMID:31048375 |
|
NCBI chr19:24,456,976...24,464,808
Ensembl chr19:24,456,976...24,464,807
|
|
G |
Ucp2 |
uncoupling protein 2 |
increases expression |
EXP |
Norepinephrine results in increased expression of UCP2 mRNA |
CTD |
PMID:8593794 PMID:12588052 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Usf1 |
upstream transcription factor 1 |
multiple interactions |
ISO |
USF1 gene polymorphism promotes the reaction [Norepinephrine results in increased metabolism of Lipids]; USF1 protein affects the reaction [Norepinephrine results in increased metabolism of Lipids] |
CTD |
PMID:15985485 |
|
NCBI chr13:89,797,750...89,805,561
Ensembl chr13:89,797,800...89,805,558
|
|
G |
Vdr |
vitamin D receptor |
increases abundance |
ISO |
VDR protein results in increased abundance of Norepinephrine |
CTD |
PMID:27450565 |
|
NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
[Cobalt co-treated with Norepinephrine] results in increased expression of VEGFA mRNA; [Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA; [Norepinephrine co-treated with Tetradecanoylphorbol Acetate] results in increased expression of VEGFA mRNA; AG 1879 inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Xbp1 |
X-box binding protein 1 |
affects localization |
EXP |
Norepinephrine affects the localization of XBP1 protein |
CTD |
PMID:16338971 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
affects response to substance |
ISO |
PTGER4 protein affects the susceptibility to 8-isoprostaglandin E2 |
CTD |
PMID:22565502 |
|
NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
|
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:17118406 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases abundance |
ISO |
[Lead co-treated with APP protein modified form] results in increased abundance of 8-epi-prostaglandin F2alpha APP protein modified form results in increased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:22610977 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance increases chemical synthesis |
ISO EXP |
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Dehydroascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; resveratrol inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] pyrrolidine dithiocarbamic acid inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]; Rotenone inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:11530235 PMID:16529823 PMID:19751497 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Pafah2 |
platelet-activating factor acetylhydrolase 2 |
affects metabolic processing multiple interactions |
ISO |
PAFAH2 protein affects the metabolism of 8-epi-prostaglandin F2alpha PAFAH2 protein affects the reaction [Carbon Tetrachloride results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:18024956 |
|
NCBI chr 5:152,606,850...152,635,956
Ensembl chr 5:152,606,847...152,634,803
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of 8-epi-prostaglandin F2alpha; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha |
CTD |
PMID:8621535 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions affects response to substance |
ISO |
8-epi-prostaglandin F2alpha binds to and results in increased activity of TBXA2R protein TBXA2R protein affects the susceptibility to 8-epi-prostaglandin F2alpha |
CTD |
PMID:18158556 PMID:22565502 |
|
NCBI chr 7:11,253,153...11,259,233
Ensembl chr 7:11,253,180...11,257,977
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases methylation increases hydroxylation increases metabolic processing |
ISO |
CYP1A1 protein results in decreased methylation of almotriptan CYP1A1 protein results in increased hydroxylation of almotriptan CYP1A1 protein results in increased metabolism of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases methylation |
ISO |
CYP1A2 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases methylation |
ISO |
CYP2C19 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases methylation |
ISO |
CYP2C8 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases methylation increases hydroxylation |
ISO |
CYP2D6 protein results in decreased methylation of almotriptan CYP2D6 protein results in increased hydroxylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases hydroxylation decreases methylation |
ISO |
CYP3A4 protein results in increased hydroxylation of almotriptan CYP3A4 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
increases oxidation |
ISO |
FMO3 protein results in increased oxidation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
ISO |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 8:89,113,984...89,130,830
Ensembl chr 8:89,129,453...89,130,991
|
|
G |
Maoa |
monoamine oxidase A |
increases metabolic processing |
ISO |
MAOA protein results in increased metabolism of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
increases expression |
EXP |
Angiotensin II results in increased expression of AGTR2 mRNA; Angiotensin II results in increased expression of AGTR2 protein |
CTD |
PMID:12969123 |
|
NCBI chr X:119,389,480...119,393,845
Ensembl chr X:119,390,013...119,393,842
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
EXP |
Angiotensin II results in increased expression of EDNRB protein |
CTD |
PMID:15007106 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
multiple interactions |
ISO |
angiotensin II inhibits reaction [fluvastatin increases expression of Nphs1 protein in kidney] |
RGD |
PMID:19188342 |
RGD:38596324 |
NCBI chr 1:88,922,346...88,950,560
Ensembl chr 1:88,922,433...88,950,559
|
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
cesium chloride inhibits the reaction [Acrolein results in increased expression of EDN1 protein] |
CTD |
PMID:22928487 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
cesium chloride inhibits the reaction [Acrolein results in increased expression of VEGFA protein] |
CTD |
PMID:22928487 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
decreases expression |
ISO |
thromboxane A2, carbocyclic results in decreased expression of TNFRSF11B mRNA |
CTD |
PMID:18264100 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
increases expression |
ISO |
thromboxane A2, carbocyclic results in increased expression of TNFSF11 mRNA |
CTD |
PMID:18264100 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
|
G |
Aacs |
acetoacetyl-CoA synthetase |
affects expression |
EXP |
Cocaine affects the expression of AACS mRNA |
CTD |
PMID:20187946 |
|
NCBI chr12:36,512,393...36,555,694
Ensembl chr12:36,512,393...36,555,694
|
|
G |
Aadac |
arylacetamide deacetylase |
decreases expression |
EXP |
Cocaine results in decreased expression of AADAC mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 2:150,146,234...150,157,480
Ensembl chr 2:150,146,234...150,157,480
|
|
G |
Aanat |
aralkylamine N-acetyltransferase |
affects response to substance |
ISO |
AANAT protein affects the susceptibility to Cocaine |
CTD |
PMID:12138020 |
|
NCBI chr10:105,568,091...105,572,407
Ensembl chr10:105,568,091...105,572,403
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
increases response to substance |
ISO |
ABAT mRNA results in increased susceptibility to Cocaine |
CTD |
PMID:10850552 |
|
NCBI chr10:7,093,406...7,200,439
Ensembl chr10:7,093,405...7,200,499
|
|
G |
Abca4 |
ATP binding cassette subfamily A member 4 |
decreases expression |
EXP |
Cocaine results in decreased expression of ABCA4 mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 2:225,645,539...225,783,288
Ensembl chr 2:225,645,568...225,783,287
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
multiple interactions |
ISO |
HDAC5 affects the reaction [Cocaine affects the expression of ABCA5 mRNA] |
CTD |
PMID:17988634 |
|
NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects expression |
EXP |
Cocaine affects the expression of ABCC3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
affects expression |
EXP |
Cocaine affects the expression of ABCC5 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
affects expression |
EXP |
Cocaine affects the expression of ABCC9 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
|
|
G |
Abcd4 |
ATP binding cassette subfamily D member 4 |
affects expression |
EXP |
Cocaine affects the expression of ABCD4 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 6:108,315,026...108,329,550
Ensembl chr 6:108,315,035...108,329,464
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of ABHD1 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr 6:26,787,807...26,792,795
Ensembl chr 6:26,784,058...26,792,808
|
|
G |
Abhd14a |
abhydrolase domain containing 14A |
affects expression |
EXP |
Cocaine affects the expression of ABHD14A mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 8:115,141,575...115,151,222
Ensembl chr 8:115,141,539...115,149,527
|
|
G |
Abhd17a |
abhydrolase domain containing 17A, depalmitoylase |
affects expression |
EXP |
Cocaine affects the expression of ABHD17A mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 7:11,992,543...12,000,978
Ensembl chr 7:11,992,543...11,998,973
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
affects expression |
ISO |
Cocaine affects the expression of ABL1 mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388 Ensembl chr 3:10,041,826...10,144,388
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
increases expression |
ISO |
Cocaine results in increased expression of ACAA1 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr 8:127,836,235...127,845,296
|
|
G |
Acan |
aggrecan |
affects expression |
EXP |
Cocaine affects the expression of ACAN mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:140,762,758...140,824,441
Ensembl chr 1:140,762,758...140,824,441
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
ACE inhibits the reaction [Cocaine affects the abundance of Dinoprostone]; ACE inhibits the reaction [Cocaine affects the abundance of Epoprostenol] |
CTD |
PMID:14738173 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
affects expression |
ISO |
Cocaine affects the expression of ACIN1 mRNA |
CTD |
PMID:15681117 |
|
NCBI chr15:33,288,369...33,333,256
Ensembl chr15:33,288,374...33,333,417
|
|
G |
Ackr2 |
atypical chemokine receptor 2 |
affects expression |
EXP |
Cocaine affects the expression of ACKR2 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 8:130,526,521...130,543,566
Ensembl chr 8:130,538,651...130,542,227
|
|
G |
Aco2 |
aconitase 2 |
increases expression |
ISO |
Cocaine results in increased expression of ACO2 protein modified form |
CTD |
PMID:24096156 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
affects expression |
EXP |
Cocaine affects the expression of ACSL5 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:276,240,703...276,290,012
Ensembl chr 1:276,240,703...276,290,008
|
|
G |
Acss1 |
acyl-CoA synthetase short-chain family member 1 |
decreases expression |
EXP |
Cocaine results in decreased expression of ACSS1 mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 3:146,420,346...146,470,293
Ensembl chr 3:146,420,346...146,470,293
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
decreases expression |
ISO |
Cocaine results in decreased expression of ACTG2 mRNA |
CTD |
PMID:20948987 |
|
NCBI chr 4:115,215,160...115,239,746
Ensembl chr 4:115,215,060...115,239,723
|
|
G |
Actn2 |
actinin alpha 2 |
increases expression |
ISO |
Cocaine results in increased expression of ACTN2 mRNA |
CTD |
PMID:15009677 PMID:16710320 |
|
NCBI chr17:66,304,530...66,397,647
Ensembl chr17:66,304,501...66,397,653
|
|
G |
Acvr1c |
activin A receptor type 1C |
increases expression |
EXP |
Cocaine results in increased expression of ACVR1C mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:44,272,859...44,342,501
Ensembl chr 3:44,270,653...44,342,355
|
|
G |
Acy3 |
aminoacylase 3 |
affects expression |
EXP |
Cocaine affects the expression of ACY3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:219,233,712...219,237,103
Ensembl chr 1:219,233,750...219,237,098
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases expression |
EXP |
Cocaine results in decreased expression of ADAM19 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr10:31,146,107...31,240,582
Ensembl chr10:31,146,107...31,240,582
|
|
G |
Adam1a |
ADAM metallopeptidase domain 1a |
multiple interactions |
ISO |
HDAC5 affects the reaction [Cocaine affects the expression of ADAM1A mRNA] |
CTD |
PMID:17988634 |
|
NCBI chr12:40,533,731...40,536,632
Ensembl chr12:40,533,632...40,536,620
|
|
G |
Adamts19 |
ADAM metallopeptidase with thrombospondin type 1 motif, 19 |
decreases expression |
EXP |
Cocaine results in decreased expression of ADAMTS19 mRNA |
CTD |
PMID:27899881 |
|
NCBI chr18:53,915,807...54,099,856
Ensembl chr18:53,915,807...54,099,120
|
|
G |
Adat2 |
adenosine deaminase, tRNA-specific 2 |
decreases expression |
EXP |
Cocaine results in decreased expression of ADAT2 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 1:7,726,447...7,743,112
Ensembl chr 1:7,726,529...7,742,484
|
|
G |
Adcy2 |
adenylate cyclase 2 |
affects expression |
EXP |
Cocaine affects the expression of ADCY2 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:37,043,071...37,698,390
Ensembl chr 1:37,507,276...37,698,390
|
|
G |
Adcy8 |
adenylate cyclase 8 |
affects expression |
EXP |
Cocaine affects the expression of ADCY8 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 7:105,353,883...105,593,372
Ensembl chr 7:105,353,913...105,592,804
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases expression multiple interactions |
ISO |
Cocaine results in increased expression of ADCYAP1 mRNA ADCYAP1 protein modified form affects the reaction [Cocaine results in increased cleavage of CASP3 protein]; ADCYAP1 protein modified form affects the reaction [Cocaine results in increased expression of BAX protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide affects the reaction [IL6 protein affects the reaction [Cocaine results in increased expression of ADCYAP1 mRNA]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Cocaine results in increased expression of ADCYAP1 mRNA]; IL6 protein affects the reaction [Cocaine results in increased expression of ADCYAP1 mRNA]; TNF protein affects the reaction [Cocaine results in increased expression of ADCYAP1 mRNA] |
CTD |
PMID:29673861 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
increases expression multiple interactions |
ISO |
Cocaine results in increased expression of ADCYAP1R1 mRNA alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide affects the reaction [IL6 protein affects the reaction [Cocaine results in increased expression of ADCYAP1R1 mRNA]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Cocaine results in increased expression of ADCYAP1R1 mRNA]; IL6 protein affects the reaction [Cocaine results in increased expression of ADCYAP1R1 mRNA]; TNF protein affects the reaction [Cocaine results in increased expression of ADCYAP1R1 mRNA] |
CTD |
PMID:29673861 |
|
NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696
|
|
G |
Adgra1 |
adhesion G protein-coupled receptor A1 |
multiple interactions |
ISO |
[Cocaine co-treated with FOS protein mutant form] results in increased expression of ADGRA1 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr 1:212,170,190...212,213,156
Ensembl chr 1:212,181,374...212,211,578
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
affects expression |
EXP |
Cocaine affects the expression of ADGRE1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 9:9,431,888...9,585,883
Ensembl chr 9:9,431,860...9,585,865
|
|
G |
Adgrf1 |
adhesion G protein-coupled receptor F1 |
decreases expression |
EXP |
Cocaine results in decreased expression of ADGRF1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 9:20,343,730...20,378,686
|
|
G |
Adgrl1 |
adhesion G protein-coupled receptor L1 |
affects expression |
EXP |
Cocaine affects the expression of ADGRL1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr19:25,029,037...25,069,146
Ensembl chr19:25,029,037...25,069,142
|
|
G |
Adgrl3 |
adhesion G protein-coupled receptor L3 |
affects expression |
EXP |
Cocaine affects the expression of ADGRL3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr14:28,362,176...29,226,085
Ensembl chr14:28,393,394...28,967,980
|
|
G |
Adora1 |
adenosine A1 receptor |
affects expression affects response to substance |
EXP ISO |
Cocaine affects the expression of ADORA1 mRNA; Cocaine affects the expression of ADORA1 protein ADORA1 affects the susceptibility to Cocaine |
CTD |
PMID:12358776 PMID:19092996 |
|
NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
|
|
G |
Adora2a |
adenosine A2a receptor |
increases response to substance increases expression |
ISO |
ADORA2A results in increased susceptibility to Cocaine Cocaine deficiency results in increased expression of ADORA2A mRNA |
CTD |
PMID:16123743 PMID:27126842 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Adora2b |
adenosine A2B receptor |
affects expression |
EXP |
Cocaine affects the expression of ADORA2B mRNA |
CTD |
PMID:20187946 |
|
NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
increases response to substance |
ISO |
ADRA1B gene results in increased susceptibility to Cocaine |
CTD |
PMID:14556232 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions affects expression |
EXP |
Betaxolol affects the reaction [Cocaine affects the expression of ADRB1 protein]; Betaxolol inhibits the reaction [Cocaine affects the expression of ADRB1 protein] |
CTD |
PMID:17513029 PMID:18596687 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Aff4 |
AF4/FMR2 family, member 4 |
increases expression |
EXP |
Cocaine results in increased expression of AFF4 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr10:38,692,167...38,773,021
Ensembl chr10:38,692,211...38,773,021
|
|
G |
Afmid |
arylformamidase |
increases expression |
EXP |
Cocaine results in increased expression of AFMID mRNA |
CTD |
PMID:17898221 |
|
NCBI chr10:106,828,963...106,844,314
Ensembl chr10:106,828,981...106,844,314
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
EXP |
Cocaine results in increased expression of AFP mRNA |
CTD |
PMID:27899881 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Agap2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
affects expression |
EXP |
Cocaine affects the expression of AGAP2 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 7:70,360,199...70,377,422
Ensembl chr 7:70,364,813...70,377,422
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
multiple interactions affects response to substance |
ISO |
AGO2 protein affects the reaction [Cocaine results in increased expression of MIR130A mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR136 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR137 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR138-1 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR148B mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR154 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR181A1 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR186 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR301B mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR324 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR337 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR369 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR376A mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR376C mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR380 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR384 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR467B mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR488 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR500 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR544 mRNA]; AGO2 protein affects the reaction [Cocaine results in increased expression of MIR665 mRNA] AGO2 protein affects the susceptibility to Cocaine |
CTD |
PMID:20643829 |
|
NCBI chr 7:114,339,607...114,377,277
Ensembl chr 7:114,339,434...114,380,613
|
|
G |
Aif1l |
allograft inflammatory factor 1-like |
decreases expression |
ISO |
Cocaine results in decreased expression of AIF1L mRNA |
CTD |
PMID:15009677 |
|
NCBI chr 3:9,237,944...9,262,628
Ensembl chr 3:9,237,944...9,262,628
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects expression increases expression |
ISO |
Cocaine affects the expression of AIFM1 mRNA Cocaine results in increased expression of AIFM1 mRNA |
CTD |
PMID:15681117 PMID:18000554 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Aifm2 |
apoptosis inducing factor, mitochondria associated 2 |
affects expression |
ISO |
Cocaine affects the expression of AIFM2 mRNA |
CTD |
PMID:15681117 |
|
NCBI chr20:31,329,047...31,353,548
Ensembl chr20:31,339,787...31,352,906
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of AK1 mRNA |
CTD |
PMID:15009677 |
|
NCBI chr 3:11,652,143...11,659,135
|
|
G |
Ak3 |
adenylate kinase 3 |
affects expression |
EXP |
Cocaine affects the expression of AK3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:247,144,486...247,169,690
Ensembl chr 1:247,144,491...247,169,693
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
affects expression |
EXP |
Cocaine affects the expression of AKR1D1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 4:65,110,706...65,143,930
Ensembl chr 4:65,110,746...65,143,941
|
|
G |
Akr1e2 |
aldo-keto reductase family 1, member E2 |
affects expression |
EXP |
Cocaine affects the expression of AKR1E1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr17:69,365,437...69,379,944
Ensembl chr17:69,365,453...69,379,947
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
affects expression |
EXP |
Cocaine affects the expression of AKR7A3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects expression multiple interactions increases phosphorylation |
EXP ISO |
Cocaine affects the expression of AKT1 mRNA [Cocaine co-treated with cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester] results in increased phosphorylation of AKT1 protein Cocaine results in increased phosphorylation of AKT1 protein Cocaine affects the reaction [ILK protein affects the phosphorylation of AKT1 protein] |
CTD |
PMID:18702665 PMID:20187946 PMID:25933444 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression |
EXP |
Cocaine results in increased expression of ALCAM mRNA |
CTD |
PMID:17898221 |
|
NCBI chr11:50,780,735...50,985,083
Ensembl chr11:50,781,127...50,985,083
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
EXP |
[[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; [ALDH2 protein affects the abundance of Tetrahydropapaveroline] which affects the susceptibility to Cocaine; ALDH2 protein affects the reaction [Cocaine results in increased abundance of Dopamine] |
CTD |
PMID:20729865 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Ambra1 |
autophagy and beclin 1 regulator 1 |
decreases expression |
EXP |
Cocaine results in decreased expression of AMBRA1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:80,634,470...80,830,068
Ensembl chr 3:80,634,470...80,830,068
|
|
G |
Amh |
anti-Mullerian hormone |
increases expression |
EXP |
Cocaine results in increased expression of AMH mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 7:11,775,155...11,777,503
Ensembl chr 7:11,775,155...11,777,503
|
|
G |
Amigo1 |
adhesion molecule with Ig like domain 1 |
affects expression |
EXP |
Cocaine affects the expression of AMIGO1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 2:210,977,125...210,982,582
Ensembl chr 2:210,977,938...210,982,579
|
|
G |
Amigo3 |
adhesion molecule with Ig like domain 3 |
affects expression |
EXP |
Cocaine affects the expression of AMIGO3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 8:116,830,773...116,832,299
|
|
G |
Amn1 |
antagonist of mitotic exit network 1 homolog |
decreases expression |
EXP |
Cocaine results in decreased expression of AMN1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 4:183,670,589...183,697,531
Ensembl chr 4:183,670,596...183,697,531
|
|
G |
Ankrd54 |
ankyrin repeat domain 54 |
affects expression |
EXP |
Cocaine affects the expression of ANKRD54 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 7:120,282,423...120,295,647
Ensembl chr 7:120,282,822...120,295,618
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
decreases expression |
EXP |
Cocaine results in decreased expression of ANKS1B mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 7:30,507,135...31,684,604
Ensembl chr 7:30,699,476...31,681,182
|
|
G |
Anxa7 |
annexin A7 |
affects expression |
EXP |
Cocaine affects the expression of ANXA7 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr15:4,254,470...4,281,296
Ensembl chr15:4,254,499...4,281,287
|
|
G |
Ap1ar |
adaptor-related protein complex 1 associated regulatory protein |
increases expression |
EXP |
Cocaine results in increased expression of AP1AR mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 2:232,146,418...232,178,813
Ensembl chr 2:232,147,690...232,178,671
|
|
G |
Ap2b1 |
adaptor related protein complex 2 subunit beta 1 |
affects expression |
EXP |
Cocaine affects the expression of AP2B1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr10:70,516,462...70,621,973
Ensembl chr10:70,520,206...70,621,977
|
|
G |
Ap2m1 |
adaptor related protein complex 2 subunit mu 1 |
increases expression |
EXP |
Cocaine results in increased expression of AP2M1 protein |
CTD |
PMID:25100957 |
|
NCBI chr11:84,041,184...84,047,542
Ensembl chr11:84,041,184...84,047,546
|
|
G |
Ap2s1 |
adaptor related protein complex 2 subunit sigma 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of AP2S1 mRNA |
CTD |
PMID:15009677 |
|
NCBI chr 1:78,671,238...78,682,847
Ensembl chr 1:78,671,121...78,682,871
|
|
G |
Ap5m1 |
adaptor related protein complex 5 subunit mu 1 |
affects expression |
EXP |
Cocaine affects the expression of AP5M1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr15:25,933,483...25,955,745
Ensembl chr15:25,933,483...25,955,745
|
|
G |
Apcs |
amyloid P component, serum |
increases expression |
ISO |
Cocaine results in increased expression of APCS protein |
CTD |
PMID:12714198 |
|
NCBI chr13:91,426,621...91,427,417
Ensembl chr13:91,426,479...91,427,575
|
|
G |
Aph1a |
aph-1 homolog A, gamma secretase subunit |
affects expression |
EXP |
Cocaine affects the expression of APH1A mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 2:198,006,247...198,009,837
Ensembl chr 2:198,006,316...198,009,830
|
|
G |
Aplnr |
apelin receptor |
increases expression |
EXP |
Cocaine results in increased expression of APLNR mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:72,540,538...72,544,183
Ensembl chr 3:72,540,538...72,544,182
|
|
G |
Apol11a |
apolipoprotein L 11a |
decreases expression |
EXP |
Cocaine results in decreased expression of APOL11A mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 7:118,835,316...118,858,347
Ensembl chr 7:118,836,547...118,840,634
|
|
G |
Apol2 |
apolipoprotein L, 2 |
increases expression |
ISO |
Cocaine results in increased expression of APOL2 mRNA |
CTD |
PMID:17205118 |
|
NCBI chr 7:118,727,658...118,735,453
Ensembl chr 7:118,728,617...118,732,738 Ensembl chr 7:118,728,617...118,732,738
|
|
G |
Apold1 |
apolipoprotein L domain containing 1 |
affects expression |
EXP |
Cocaine affects the expression of APOLD1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 4:168,752,142...168,755,024
Ensembl chr 4:168,752,133...168,755,023
|
|
G |
Apoo |
apolipoprotein O |
increases expression |
EXP |
Cocaine results in increased expression of APOO protein |
CTD |
PMID:25100957 |
|
NCBI chr X:63,521,033...63,625,134
Ensembl chr X:63,520,991...63,625,134
|
|
G |
App |
amyloid beta precursor protein |
decreases expression increases expression |
EXP ISO |
Cocaine results in decreased expression of APP mRNA Cocaine results in increased expression of APP mRNA |
CTD |
PMID:15009677 PMID:16710320 PMID:17898221 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
increases expression |
EXP |
Cocaine results in increased expression of APPL1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr16:2,560,103...2,602,035
Ensembl chr16:2,563,520...2,602,103
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
affects expression increases expression multiple interactions |
EXP |
Cocaine affects the expression of ARC mRNA Cocaine results in increased expression of ARC mRNA; Cocaine results in increased expression of ARC protein Reserpine inhibits the reaction [Cocaine results in increased expression of ARC mRNA] |
CTD |
PMID:7722525 PMID:12117546 PMID:15254092 PMID:17851536 PMID:18311559 PMID:18361437 PMID:20187946 PMID:24810662 |
|
NCBI chr 7:115,907,097...115,911,059
Ensembl chr 7:115,907,097...115,910,541
|
|
G |
Arf4 |
ADP-ribosylation factor 4 |
decreases expression |
EXP |
Cocaine results in decreased expression of ARF4 protein |
CTD |
PMID:25100957 |
|
NCBI chr16:2,338,333...2,354,909
Ensembl chr16:2,338,333...2,354,909
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
increases expression |
EXP |
Cocaine results in increased expression of ARHGAP1 protein |
CTD |
PMID:25100957 |
|
NCBI chr 3:80,555,196...80,576,881
Ensembl chr 3:80,555,196...80,576,856
|
|
G |
Arhgap29 |
Rho GTPase activating protein 29 |
decreases expression |
ISO |
Cocaine results in decreased expression of ARHGAP29 mRNA |
CTD |
PMID:12629581 |
|
NCBI chr 2:225,552,075...225,613,349
Ensembl chr 2:225,552,148...225,613,359
|
|
G |
Arhgap30 |
Rho GTPase activating protein 30 |
increases expression |
EXP |
Cocaine results in increased expression of ARHGAP30 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr13:89,774,764...89,796,113
Ensembl chr13:89,774,764...89,796,113
|
|
G |
Arhgap44 |
Rho GTPase activating protein 44 |
decreases expression |
EXP |
Cocaine results in decreased expression of ARHGAP44 protein |
CTD |
PMID:25100957 |
|
NCBI chr10:51,501,547...51,669,546
Ensembl chr10:51,502,894...51,669,297
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
increases expression |
EXP |
Cocaine results in increased expression of ARHGAP5 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 6:73,345,129...73,408,304
Ensembl chr 6:73,345,392...73,405,880
|
|
G |
Arhgap9 |
Rho GTPase activating protein 9 |
decreases expression |
EXP |
Cocaine results in decreased expression of ARHGAP9 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 7:70,612,650...70,620,900
Ensembl chr 7:70,612,103...70,620,890
|
|
G |
Arhgef1 |
Rho guanine nucleotide exchange factor 1 |
affects expression |
EXP |
Cocaine affects the expression of ARHGEF1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:81,769,212...81,797,237
Ensembl chr 1:81,779,380...81,797,236
|
|
G |
Arhgef7 |
Rho guanine nucleotide exchange factor 7 |
affects expression |
EXP |
Cocaine affects the expression of ARHGEF7 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr16:83,006,732...83,117,065
Ensembl chr16:83,006,718...83,132,785
|
|
G |
Armcx6 |
armadillo repeat containing, X-linked 6 |
affects expression |
EXP |
Cocaine affects the expression of ARMCX6 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr X:105,565,733...105,573,387
Ensembl chr X:105,565,747...105,568,343
|
|
G |
Arntl |
aryl hydrocarbon receptor nuclear translocator-like |
decreases expression |
ISO |
Cocaine results in decreased expression of ARNTL mRNA |
CTD |
PMID:15994025 |
|
NCBI chr 1:178,039,002...178,137,469
Ensembl chr 1:178,039,063...178,137,465
|
|
G |
Arpc1a |
actin related protein 2/3 complex, subunit 1A |
increases expression |
EXP |
Cocaine results in increased expression of ARPC1A protein |
CTD |
PMID:25100957 |
|
NCBI chr12:11,272,609...11,294,084
Ensembl chr12:11,272,609...11,294,058
|
|
G |
Arpp19 |
cAMP-regulated phosphoprotein 19 |
multiple interactions |
EXP |
Cocaine inhibits the reaction [SK&F 81297 results in increased phosphorylation of ARPP19 protein] |
CTD |
PMID:11268215 |
|
NCBI chr 8:81,949,577...81,972,054
Ensembl chr 8:81,949,877...81,968,589
|
|
G |
Arpp21 |
cAMP regulated phosphoprotein 21 |
multiple interactions increases expression |
EXP ISO |
Cocaine inhibits the reaction [SK&F 81297 results in increased phosphorylation of ARPP21 protein] Cocaine deficiency results in increased expression of ARPP21 mRNA |
CTD |
PMID:11268215 PMID:27126842 |
|
NCBI chr 8:120,323,895...120,492,790
Ensembl chr 8:120,323,897...120,446,507
|
|
G |
Art5 |
ADP-ribosyltransferase 5 |
increases expression |
EXP |
Cocaine results in increased expression of ART5 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 1:167,192,809...167,202,767
Ensembl chr 1:167,192,810...167,202,767
|
|
G |
As3mt |
arsenite methyltransferase |
affects expression |
EXP |
Cocaine affects the expression of AS3MT mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:266,482,787...266,514,570
Ensembl chr 1:266,482,858...266,514,569
|
|
G |
Asap1 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 |
decreases expression |
EXP |
Cocaine results in decreased expression of ASAP1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 7:104,670,076...104,951,090
Ensembl chr 7:104,669,672...104,801,045
|
|
G |
Atad1 |
ATPase family, AAA domain containing 1 |
increases expression |
EXP |
Cocaine results in increased expression of ATAD1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 1:251,234,702...251,386,996
Ensembl chr 1:251,235,508...251,387,002
|
|
G |
Atad5 |
ATPase family, AAA domain containing 5 |
decreases expression |
EXP |
Cocaine results in decreased expression of ATAD5 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr10:67,427,042...67,475,825
Ensembl chr10:67,427,066...67,473,649
|
|
G |
Ate1 |
arginyltransferase 1 |
increases expression |
EXP |
Cocaine results in increased expression of ATE1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 1:200,810,741...200,885,593 NCBI chr 1:200,958,564...201,082,100
Ensembl chr 1:200,810,771...201,082,727
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression decreases expression |
EXP |
Cocaine results in increased expression of ATF3 mRNA Cocaine results in decreased expression of ATF3 mRNA |
CTD |
PMID:23644055 PMID:27899881 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
EXP |
Cocaine results in increased expression of ATF4; Cocaine results in increased expression of ATF4 mRNA |
CTD |
PMID:18593214 PMID:23644055 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atf6 |
activating transcription factor 6 |
affects expression |
EXP |
Cocaine affects the expression of ATF6 mRNA |
CTD |
PMID:23644055 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Atf7 |
activating transcription factor 7 |
affects expression |
ISO |
Cocaine affects the expression of ATF7 mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 7:144,131,382...144,223,463
Ensembl chr 7:144,136,325...144,223,429
|
|
G |
Atg2b |
autophagy related 2B |
affects expression |
EXP |
Cocaine affects the expression of ATG2B mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 6:129,449,451...129,519,599
Ensembl chr 6:129,449,449...129,509,720
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
affects expression |
EXP |
Cocaine affects the expression of ATG4B mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 9:100,888,457...100,920,123
Ensembl chr 9:100,888,501...100,918,637
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression |
ISO |
EHMT2 inhibits the reaction [Cocaine results in increased expression of ATM mRNA] |
CTD |
PMID:20056891 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp10a |
ATPase phospholipid transporting 10A (putative) |
decreases expression |
EXP |
Cocaine results in decreased expression of ATP10A mRNA |
CTD |
PMID:17898221 PMID:27899881 |
|
NCBI chr 1:115,973,343...116,141,892
Ensembl chr 1:115,975,324...116,141,892
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
affects expression |
ISO |
Cocaine affects the expression of ATP1A1 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr 2:204,003,742...204,032,023
Ensembl chr 2:204,003,742...204,032,023
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
increases expression affects expression |
EXP |
Cocaine results in increased expression of ATP1A3 mRNA Cocaine affects the expression of ATP1A3 mRNA |
CTD |
PMID:16076954 PMID:20187946 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
increases expression |
EXP |
Cocaine results in increased expression of ATP1B2 mRNA |
CTD |
PMID:16076954 |
|
NCBI chr10:56,205,622...56,211,879
Ensembl chr10:56,205,625...56,211,891
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
increases expression multiple interactions |
ISO |
Cocaine results in increased expression of ATP1B3 mRNA FOS protein mutant form inhibits the reaction [Cocaine results in increased expression of ATP1B3 mRNA] |
CTD |
PMID:18355967 |
|
NCBI chr 8:104,190,032...104,221,342
Ensembl chr 8:104,190,032...104,221,342
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
affects expression |
ISO |
Cocaine affects the expression of ATP5F1A protein |
CTD |
PMID:19393250 |
|
NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
Cocaine results in decreased expression of ATP5F1B protein |
CTD |
PMID:17075605 |
|
NCBI chr 7:2,504,708...2,511,748
Ensembl chr 7:2,504,695...2,511,749
|
|
G |
Atp5f1e |
ATP synthase F1 subunit epsilon |
affects expression |
EXP |
Cocaine affects the expression of ATP5F1E mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 3:172,563,105...172,566,007
Ensembl chr 3:172,563,105...172,566,010
|
|
G |
Atp5mc3 |
ATP synthase membrane subunit c locus 3 |
decreases expression affects expression |
ISO EXP |
Cocaine results in decreased expression of ATP5MC3 mRNA Cocaine affects the expression of ATP5MC3 mRNA |
CTD |
PMID:12629581 PMID:20187946 |
|
NCBI chr 3:60,811,218...60,813,903
Ensembl chr 3:60,811,210...60,813,869
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
affects expression |
EXP |
Cocaine affects the expression of ATP5PB mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 2:208,566,385...208,577,147
Ensembl chr 2:208,566,385...208,577,146 Ensembl chr 2:208,566,385...208,577,146
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
affects expression |
EXP |
Cocaine affects the expression of ATP5H mRNA |
CTD |
PMID:12358776 |
|
NCBI chr10:103,967,340...103,972,552
Ensembl chr10:103,967,312...103,972,668
|
|
G |
Atp6v1d |
ATPase H+ transporting V1 subunit D |
affects expression |
EXP |
Cocaine affects the expression of ATP6V1D mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 6:102,032,271...102,047,754
Ensembl chr 6:102,032,276...102,047,758
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
increases expression multiple interactions |
ISO |
Cocaine results in increased expression of ATP8B2 mRNA FOS protein mutant form inhibits the reaction [Cocaine results in increased expression of ATP8B2 mRNA] |
CTD |
PMID:18355967 |
|
NCBI chr 2:189,285,961...189,306,947
Ensembl chr 2:189,285,953...189,307,108
|
|
G |
Atp9b |
ATPase phospholipid transporting 9B (putative) |
affects response to substance |
ISO |
ATP9B gene SNP affects the susceptibility to Cocaine |
CTD |
PMID:18438686 |
|
NCBI chr18:77,343,551...77,535,608
Ensembl chr18:77,343,551...77,535,593
|
|
G |
Atpaf1 |
ATP synthase mitochondrial F1 complex assembly factor 1 |
multiple interactions |
ISO |
[Cocaine co-treated with FOS protein mutant form] results in decreased expression of ATPAF1 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr 5:134,641,618...134,667,079
Ensembl chr 5:134,641,608...134,667,084
|
|
G |
Atrx |
ATRX, chromatin remodeler |
increases expression |
EXP |
Cocaine results in increased expression of ATRX mRNA |
CTD |
PMID:17898221 |
|
NCBI chr X:76,820,110...76,979,155
Ensembl chr X:76,692,970...76,708,878 Ensembl chr X:76,692,970...76,708,878
|
|
G |
Atxn1 |
ataxin 1 |
affects expression |
EXP |
Cocaine affects the expression of ATXN1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr17:19,160,986...19,533,814
Ensembl chr17:19,249,952...19,533,814
|
|
G |
Atxn3 |
ataxin 3 |
decreases expression |
ISO |
Cocaine results in decreased expression of ATXN3 mRNA |
CTD |
PMID:12629581 |
|
NCBI chr 6:125,817,420...125,853,461
Ensembl chr 6:125,819,640...125,853,461
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc-binding |
decreases expression |
EXP |
Cocaine results in decreased expression of AZGP1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr12:19,196,565...19,203,094
Ensembl chr12:19,196,611...19,202,647
|
|
G |
Baalc |
BAALC binder of MAP3K1 and KLF4 |
decreases expression |
ISO |
Cocaine results in decreased expression of BAALC mRNA |
CTD |
PMID:18355967 |
|
NCBI chr 7:77,761,056...77,836,534
Ensembl chr 7:77,763,512...77,837,453
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression |
EXP |
Cocaine results in increased expression of BACH1 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842 Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bach2 |
BTB domain and CNC homolog 2 |
affects expression |
ISO |
Cocaine affects the expression of BACH2 mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 5:47,458,891...47,807,176
Ensembl chr 5:47,546,014...47,807,166
|
|
G |
Bad |
BCL2-associated agonist of cell death |
affects expression |
ISO |
Cocaine affects the expression of BAD mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bag1 |
BAG cochaperone 1 |
affects expression |
ISO |
Cocaine affects the expression of BAG1 mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
|
|
G |
Bag3 |
BAG cochaperone 3 |
affects expression increases expression |
ISO EXP |
Cocaine affects the expression of BAG3 mRNA Cocaine results in increased expression of BAG3 mRNA |
CTD |
PMID:15681117 PMID:27899881 |
|
NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
affects expression |
EXP |
Cocaine affects the expression of BAMBI mRNA |
CTD |
PMID:20187946 |
|
NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992
|
|
G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
affects expression |
EXP |
Cocaine affects the expression of BASP1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 2:77,586,424...77,632,626
Ensembl chr 2:77,586,424...77,632,628
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions increases activity affects expression |
ISO EXP |
Cocaine results in increased expression of BAX mRNA ADCYAP1 protein modified form affects the reaction [Cocaine results in increased expression of BAX protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide affects the reaction [Cocaine results in increased expression of BAX protein]; IL6 protein affects the reaction [Cocaine results in increased expression of BAX protein]; TNF protein affects the reaction [Cocaine results in increased expression of BAX protein]; TNF protein affects the reaction [IL6 protein affects the reaction [Cocaine results in increased expression of BAX protein]] Cocaine results in increased activity of BAX protein Cocaine affects the expression of BAX mRNA |
CTD |
PMID:11392460 PMID:15681117 PMID:15685203 PMID:17084983 PMID:17635674 PMID:18974856 PMID:20948987 PMID:29673861 PMID:30393195 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Baz1b |
bromodomain adjacent to zinc finger domain, 1B |
multiple interactions increases expression |
ISO |
[SMARCA5 protein co-treated with BAZ1B protein] results in increased susceptibility to Cocaine; Cocaine promotes the reaction [BAZ1B protein binds to SPHKAP gene]; Cocaine results in increased expression of and affects the activity of BAZ1B protein Cocaine results in increased expression of BAZ1B mRNA |
CTD |
PMID:27053203 |
|
NCBI chr12:24,478,882...24,536,851
Ensembl chr12:24,478,898...24,537,313
|
|
G |
Baz2b |
bromodomain adjacent to zinc finger domain, 2B |
increases expression |
EXP |
Cocaine results in increased expression of BAZ2B mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:45,968,845...46,286,915
Ensembl chr 3:45,968,825...46,153,371
|
|
G |
Bcap31 |
B-cell receptor-associated protein 31 |
affects expression |
EXP |
Cocaine affects the expression of BCAP31 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr X:157,094,365...157,126,397
Ensembl chr X:157,095,937...157,126,393
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
affects expression |
EXP |
Cocaine affects the expression of BCAT1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
|
|
G |
Bche |
butyrylcholinesterase |
affects metabolic processing multiple interactions increases hydrolysis increases metabolic processing decreases response to substance affects hydrolysis decreases metabolic processing affects degradation |
ISO |
BCHE protein affects the metabolism of Cocaine [BCHE protein mutant form results in increased metabolism of Cocaine] which results in increased chemical synthesis of Benzoic Acid; [BCHE protein mutant form results in increased metabolism of Cocaine] which results in increased chemical synthesis of ecgonine methyl ester [BCHE protein mutant form results in increased hydrolysis of Cocaine] which results in increased abundance of Benzoic Acid; [BCHE protein mutant form results in increased hydrolysis of Cocaine] which results in increased abundance of ecgonine methyl ester BCHE protein mutant form results in increased metabolism of Cocaine; BCHE protein results in increased metabolism of Cocaine BCHE protein mutant form results in decreased susceptibility to Cocaine BCHE protein modified form results in increased hydrolysis of Cocaine; BCHE protein mutant form results in increased hydrolysis of Cocaine BCHE protein affects the hydrolysis of Cocaine BCHE protein mutant form results in decreased metabolism of Cocaine BCHE protein mutant form affects the degradation of Cocaine |
CTD |
PMID:572161 PMID:16275916 PMID:17989928 PMID:18514178 PMID:18514640 PMID:19067679 PMID:20060817 PMID:20219449 PMID:20971807 PMID:22917637 PMID:22960160 PMID:24582612 PMID:25814464 PMID:27154495 PMID:30080993 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl11b |
BAF chromatin remodeling complex subunit BCL11B |
increases expression |
ISO |
Cocaine deficiency results in increased expression of BCL11B mRNA |
CTD |
PMID:27126842 |
|
NCBI chr 6:131,834,097...131,927,251
Ensembl chr 6:131,834,097...131,926,272
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression multiple interactions decreases expression increases phosphorylation increases expression |
ISO EXP |
Cocaine affects the expression of BCL2 mRNA IL6 protein affects the reaction [Cocaine results in decreased expression of BCL2 protein]; PRKCD protein affects the reaction [Cocaine results in decreased expression of BCL2 protein]; rottlerin inhibits the reaction [Cocaine results in decreased expression of BCL2 protein]; TNF protein affects the reaction [Cocaine results in decreased expression of BCL2 protein]; TNF protein affects the reaction [IL6 protein affects the reaction [Cocaine results in decreased expression of BCL2 protein]] Cocaine results in increased phosphorylation of BCL2 protein 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Cocaine results in increased phosphorylation of BCL2 protein]; 7-(hydroxyimino)cyclopropan(b)chromen-1a-carbxoylic acid ethyl ester inhibits the reaction [Cocaine results in increased phosphorylation of BCL2 protein]; Dizocilpine Maleate inhibits the reaction [Cocaine results in increased phosphorylation of BCL2 protein]; ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate inhibits the reaction [Cocaine results in increased phosphorylation of BCL2 protein]; SCH 23390 inhibits the reaction [Cocaine results in increased phosphorylation of BCL2 protein] Cocaine results in decreased expression of BCL2 mRNA; Cocaine results in decreased expression of BCL2 protein Cocaine results in increased expression of BCL2 protein |
CTD |
PMID:11392460 PMID:15365088 PMID:15681117 PMID:15685203 PMID:17084983 PMID:18974856 PMID:19183502 PMID:19879923 PMID:29673861 PMID:30393195 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression decreases expression multiple interactions |
EXP ISO |
Cocaine results in increased expression of BCL2L1 mRNA; Cocaine results in increased expression of BCL2L1 mRNA alternative form Cocaine results in decreased expression of BCL2L1 protein IL6 protein affects the reaction [Cocaine results in decreased expression of BCL2L1 protein]; PRKCD protein affects the reaction [Cocaine results in decreased expression of BCL2L1 protein]; rottlerin inhibits the reaction [Cocaine results in decreased expression of BCL2L1 protein]; TNF protein affects the reaction [Cocaine results in decreased expression of BCL2L1 protein]; TNF protein affects the reaction [IL6 protein affects the reaction [Cocaine results in decreased expression of BCL2L1 protein]] |
CTD |
PMID:16076954 PMID:29673861 PMID:30393195 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
increases expression |
EXP |
Cocaine results in increased expression of BCL2L11 mRNA |
CTD |
PMID:16076954 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases response to substance increases expression decreases activity affects expression multiple interactions decreases expression increases response to substance |
ISO EXP |
BDNF mRNA results in decreased susceptibility to Cocaine; BDNF protein results in decreased susceptibility to Cocaine Cocaine results in increased expression of BDNF mRNA Cocaine results in decreased activity of BDNF protein Cocaine results in increased expression of BDNF protein Cocaine affects the expression of BDNF exon; Cocaine affects the expression of BDNF mRNA; Cocaine affects the expression of BDNF protein BDNF protein inhibits the reaction [Cocaine results in increased abundance of Amino Acids, Peptides, and Proteins]; Cocaine affects the activity of and affects the expression of BDNF protein; Cocaine affects the reaction [CREB1 modified form binds to BDNF promoter]; Cocaine affects the reaction [MECP2 protein affects the expression of BDNF protein]; Cocaine affects the reaction [MECP2 protein binds to and results in decreased activity of BDNF promoter]; Cocaine affects the reaction [MIR212 protein affects the expression of BDNF protein] BDNF mRNA results in decreased susceptibility to Cocaine; BDNF protein results in decreased susceptibility to Cocaine; BDNF results in decreased susceptibility to Cocaine (+)-JQ1 compound inhibits the reaction [Cocaine promotes the reaction [BRD4 protein binds to BDNF promoter]]; (+)-JQ1 compound inhibits the reaction [Cocaine results in increased expression of BDNF mRNA]; Cocaine inhibits the reaction [CREB1 protein binds to BDNF promoter]; Cocaine inhibits the reaction [MECP2 protein binds to BDNF promoter]; Cocaine promotes the reaction [BRD4 protein binds to BDNF promoter]; FOS protein mutant form inhibits the reaction [Cocaine results in decreased expression of BDNF mRNA]; Haloperidol inhibits the reaction [Cocaine results in decreased expression of BDNF protein] Cocaine results in decreased expression of BDNF mRNA; Cocaine results in decreased expression of BDNF protein BDNF results in increased susceptibility to Cocaine |
CTD |
PMID:12099907 PMID:14973246 PMID:16423334 PMID:17194538 PMID:17618281 PMID:18311559 PMID:18355967 PMID:19321768 PMID:20554863 PMID:20711185 PMID:20810894 PMID:20826313 PMID:24358339 PMID:26558777 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Begain |
brain-enriched guanylate kinase-associated |
affects expression |
EXP |
Cocaine affects the expression of BEGAIN mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 6:132,936,964...132,972,569
Ensembl chr 6:132,936,970...132,972,511
|
|
G |
Bhlhe22 |
basic helix-loop-helix family, member e22 |
increases expression |
EXP |
Cocaine results in increased expression of BHLHE22 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 2:102,685,513...102,688,624
Ensembl chr 2:102,685,513...102,688,624
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
affects expression |
EXP |
Cocaine affects the expression of BHLHE40 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
|
|
G |
Bid |
BH3 interacting domain death agonist |
affects expression |
ISO |
Cocaine affects the expression of BID mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Bik |
BCL2-interacting killer |
affects expression |
ISO |
Cocaine affects the expression of BIK mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Bmp2k |
BMP-2 inducible kinase |
affects expression |
EXP |
Cocaine affects the expression of BMP2K mRNA |
CTD |
PMID:20187946 |
|
NCBI chr14:14,126,086...14,226,823
Ensembl chr14:14,129,725...14,192,048
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
increases expression |
EXP |
Cocaine results in increased expression of BMPR2 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 9:66,568,074...66,683,019
Ensembl chr 9:66,568,074...66,676,494
|
|
G |
Bnip2 |
BCL2 interacting protein 2 |
affects expression |
ISO |
Cocaine affects the expression of BNIP2 mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 8:76,400,333...76,426,307
Ensembl chr 8:76,400,341...76,426,503
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
affects expression |
ISO |
Cocaine affects the expression of BNIP3 mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
affects expression |
ISO |
Cocaine affects the expression of BNIP3L mRNA |
CTD |
PMID:15681117 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Brd4 |
bromodomain containing 4 |
multiple interactions increases expression |
ISO EXP |
(+)-JQ1 compound inhibits the reaction [Cocaine promotes the reaction [BRD4 protein binds to BDNF promoter]]; Cocaine promotes the reaction [BRD4 protein binds to BDNF promoter] Cocaine results in increased expression of BRD4 protein |
CTD |
PMID:26558777 |
|
NCBI chr 7:14,222,101...14,303,055
Ensembl chr 7:14,222,101...14,303,055
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
affects expression |
EXP |
Cocaine affects the expression of BSCL2 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:225,035,956...225,046,137
Ensembl chr 1:225,037,737...225,046,040
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
affects expression |
EXP |
Cocaine affects the expression of BST1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr14:71,798,218...71,814,540
Ensembl chr14:71,798,651...71,814,523
|
|
G |
Btbd9 |
BTB domain containing 9 |
increases expression |
EXP |
Cocaine results in increased expression of BTBD9 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr20:8,899,286...9,253,936
Ensembl chr20:8,901,931...9,249,820
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
affects expression |
EXP |
Cocaine affects the expression of BTG2 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Btk |
Bruton tyrosine kinase |
decreases expression |
EXP |
Cocaine results in decreased expression of BTK mRNA |
CTD |
PMID:17898221 |
|
NCBI chr X:105,360,922...105,390,580
Ensembl chr X:105,360,922...105,390,580
|
|
G |
C1qbp |
complement C1q binding protein |
decreases expression |
EXP |
Cocaine results in decreased expression of C1QBP protein |
CTD |
PMID:25100957 |
|
NCBI chr10:57,613,876...57,618,527
Ensembl chr10:57,613,879...57,618,527
|
|
G |
C1qtnf1 |
C1q and TNF related 1 |
affects expression |
EXP |
Cocaine affects the expression of C1QTNF1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr10:107,455,845...107,477,160
Ensembl chr10:107,455,845...107,477,162
|
|
G |
C1qtnf4 |
C1q and TNF related 4 |
decreases expression |
EXP |
Cocaine results in decreased expression of C1QTNF4 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:79,713,580...79,718,018
Ensembl chr 3:79,713,567...79,718,025
|
|
G |
C2cd3 |
C2 domain containing 3 centriole elongation regulator |
decreases expression |
EXP |
Cocaine results in decreased expression of C2CD3 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 1:165,382,279...165,480,088
Ensembl chr 1:165,382,690...165,479,655
|
|
G |
C2cd4d |
C2 calcium-dependent domain containing 4D |
decreases expression |
EXP |
Cocaine results in decreased expression of C2CD4D mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 2:195,599,706...195,604,730
Ensembl chr 2:195,603,599...195,604,624
|
|
G |
Ca4 |
carbonic anhydrase 4 |
decreases expression |
EXP |
Cocaine results in decreased expression of CAR4 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr10:72,272,286...72,281,069
Ensembl chr10:72,272,248...72,281,067
|
|
G |
Cab39l |
calcium binding protein 39-like |
multiple interactions |
ISO |
[Cocaine co-treated with FOS protein mutant form] results in increased expression of CAB39L mRNA |
CTD |
PMID:18355967 |
|
NCBI chr15:39,745,124...39,849,022
Ensembl chr15:39,759,257...39,870,208
|
|
G |
Cacna1d |
calcium voltage-gated channel subunit alpha1 D |
affects response to substance |
ISO |
CACNA1D polymorphism affects the susceptibility to Cocaine |
CTD |
PMID:28194001 |
|
NCBI chr16:6,110,294...6,405,022
Ensembl chr16:6,112,150...6,405,117
|
|
G |
Cacnb3 |
calcium voltage-gated channel auxiliary subunit beta 3 |
affects expression |
EXP |
Cocaine affects the expression of CACNB3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 7:140,311,120...140,324,902
Ensembl chr 7:140,315,368...140,324,902
|
|
G |
Cald1 |
caldesmon 1 |
affects expression |
EXP |
Cocaine affects the expression of CALD1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Calm1 |
calmodulin 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of CALM1 mRNA |
CTD |
PMID:17205118 |
|
NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292
|
|
G |
Calm2 |
calmodulin 2 |
decreases expression |
ISO |
Cocaine results in decreased expression of CALM2 mRNA |
CTD |
PMID:17205118 |
|
NCBI chr 6:11,067,675...11,080,078
Ensembl chr15:65,506,874...65,507,968
|
|
G |
Calr |
calreticulin |
decreases expression multiple interactions affects expression |
ISO EXP |
Cocaine results in decreased expression of CALR mRNA FOS protein mutant form inhibits the reaction [Cocaine results in decreased expression of CALR mRNA] Cocaine affects the expression of CALR mRNA |
CTD |
PMID:18355967 PMID:20187946 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Caly |
calcyon neuron-specific vesicular protein |
increases expression |
EXP |
Cocaine results in increased expression of CALY mRNA |
CTD |
PMID:20171207 |
|
NCBI chr 1:212,537,851...212,549,040
Ensembl chr 1:212,537,848...212,549,477
|
|
G |
Camk1g |
calcium/calmodulin-dependent protein kinase IG |
multiple interactions |
ISO |
[Cocaine co-treated with FOS protein mutant form] results in increased expression of CAMK1G mRNA |
CTD |
PMID:18355967 |
|
NCBI chr13:112,075,689...112,099,472
Ensembl chr13:112,075,690...112,099,336
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
affects response to substance multiple interactions increases expression |
ISO EXP |
CAMK2A affects the susceptibility to Cocaine Cocaine results in increased expression of and results in increased phosphorylation of CAMK2A protein; Nifedipine inhibits the reaction [Cocaine results in increased expression of and results in increased phosphorylation of CAMK2A protein] Cocaine results in increased expression of CAMK2A protein 7-chlorokynurenic acid inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of CAMK2A protein]; Cocaine promotes the reaction [DRD3 protein binds to CAMK2A protein]; Cocaine results in increased phosphorylation of and results in increased activity of CAMK2A protein; KN 93 inhibits the reaction [Cocaine promotes the reaction [DRD3 protein binds to CAMK2A protein]]; Sodium Benzoate promotes the reaction [Cocaine results in increased phosphorylation of and results in increased activity of CAMK2A protein] |
CTD |
PMID:14725635 PMID:17609678 PMID:19217379 PMID:28194001 |
|
NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression affects expression |
ISO EXP |
Cocaine results in decreased expression of CAMK2B mRNA Cocaine affects the expression of CAMK2B mRNA |
CTD |
PMID:17205118 PMID:20187946 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
increases response to substance decreases response to substance |
ISO |
CAMK4 promoter SNP results in increased susceptibility to Cocaine CAMK4 protein results in decreased susceptibility to Cocaine |
CTD |
PMID:19001277 |
|
NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
|
|
G |
Cap2 |
cyclase associated actin cytoskeleton regulatory protein 2 |
affects expression |
EXP |
Cocaine affects the expression of CAP2 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr17:18,441,614...18,592,866
Ensembl chr17:18,442,127...18,592,750
|
|
G |
Capzb |
capping actin protein of muscle Z-line subunit beta |
decreases expression |
ISO |
Cocaine results in decreased expression of CAPZB mRNA |
CTD |
PMID:12629581 |
|
NCBI chr 5:157,642,742...157,742,487
Ensembl chr 5:157,642,751...157,742,478
|
|
G |
Card11 |
caspase recruitment domain family, member 11 |
decreases expression |
EXP |
Cocaine results in decreased expression of CARD11 mRNA |
CTD |
PMID:27899881 |
|
NCBI chr12:15,700,600...15,844,512
Ensembl chr12:15,700,825...15,844,512
|
|
G |
Carm1 |
coactivator-associated arginine methyltransferase 1 |
affects expression |
EXP |
Cocaine affects the expression of CARM1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 8:22,577,723...22,622,555
Ensembl chr 8:22,577,715...22,622,560
|
|
G |
Carnmt1 |
carnosine N-methyltransferase 1 |
affects expression |
EXP |
Cocaine affects the expression of CARNMT1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:234,675,442...234,704,856
Ensembl chr 1:234,677,692...234,704,792
|
|
G |
Cartpt |
CART prepropeptide |
increases expression affects expression |
ISO EXP |
Cocaine results in increased expression of CARTPT mRNA Cocaine affects the expression of CARTPT mRNA |
CTD |
PMID:15009677 PMID:17851536 PMID:20187946 |
|
NCBI chr 2:30,125,249...30,127,408
Ensembl chr 2:30,125,249...30,127,269
|
|
G |
Casp2 |
caspase 2 |
increases activity increases expression |
EXP |
Cocaine results in increased activity of CASP2 protein Cocaine results in increased expression of CASP2 mRNA |
CTD |
PMID:16076954 PMID:16638611 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
increases expression increases cleavage multiple interactions increases activity affects expression |
ISO EXP |
Cocaine results in increased expression of CASP3 protein Cocaine results in increased cleavage of CASP3 protein ADCYAP1 protein modified form affects the reaction [Cocaine results in increased cleavage of CASP3 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide affects the reaction [Cocaine results in increased cleavage of CASP3 protein]; IL6 protein affects the reaction [Cocaine results in increased cleavage of CASP3 protein]; PRKCD protein affects the reaction [Cocaine results in increased cleavage of CASP3 protein]; rottlerin inhibits the reaction [Cocaine results in increased cleavage of CASP3 protein]; TNF protein affects the reaction [Cocaine results in increased cleavage of CASP3 protein]; TNF protein affects the reaction [IL6 protein affects the reaction [Cocaine results in increased cleavage of CASP3 protein]] Cocaine results in increased activity of CASP3 protein Cocaine affects the expression of CASP3 protein [Heroin co-treated with Cocaine] results in increased activity of CASP3 protein; Cocaine results in increased cleavage of and results in increased activity of CASP3 protein; Heroin promotes the reaction [Cocaine results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Cocaine results in increased activity of CASP3 protein] Cocaine affects the expression of CASP3 mRNA |
CTD |
PMID:10604926 PMID:11392460 PMID:12639677 PMID:14741756 PMID:15365088 PMID:15681117 PMID:16179556 PMID:16638611 PMID:16686379 PMID:17084983 PMID:17635674 PMID:18974856 PMID:19183502 PMID:20600547 PMID:29673861 PMID:30393195 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
affects expression decreases expression |
ISO |
Cocaine affects the expression of CASP4 mRNA Cocaine results in decreased expression of CASP4 mRNA |
CTD |
PMID:12629581 PMID:15681117 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp8 |
caspase 8 |
affects expression increases activity |
ISO EXP |
Cocaine affects the expression of CASP8 mRNA Cocaine results in increased activity of CASP8 protein |
CTD |
PMID:11392460 PMID:15681117 PMID:18974856 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
affects expression increases activity multiple interactions increases expression |
ISO EXP |
Cocaine affects the expression of CASP9 mRNA Cocaine results in increased activity of CASP9 protein SB 203580 inhibits the reaction [Cocaine results in increased activity of CASP9 protein] Cocaine affects the expression of CASP9 protein Cocaine results in increased expression of CASP9 protein |
CTD |
PMID:10604926 PMID:11392460 PMID:12639677 PMID:15365088 PMID:15681117 PMID:16179556 PMID:16638611 PMID:16686379 PMID:17084983 PMID:17635674 PMID:18974856 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Castor1 |
cytosolic arginine sensor for mTORC1 subunit 1 |
affects expression |
EXP |
Cocaine affects the expression of CASTOR1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr14:84,447,552...84,457,396
Ensembl chr14:84,447,885...84,452,367
|
|
G |
Cat |
catalase |
decreases activity increases activity increases expression |
ISO EXP |
Cocaine results in decreased activity of CAT protein Cocaine results in increased activity of CAT protein Cocaine results in increased expression of CAT protein |
CTD |
PMID:14576513 PMID:16085363 PMID:29475069 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Catsper2 |
cation channel, sperm associated 2 |
increases expression |
EXP |
Cocaine results in increased expression of CATSPER2 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:113,357,361...113,379,498
Ensembl chr 3:113,357,365...113,376,751
|
|
G |
Cbln1 |
cerebellin 1 precursor |
multiple interactions |
ISO |
[Cocaine co-treated with FOS protein mutant form] results in increased expression of CBLN1 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr19:20,607,507...20,611,316
Ensembl chr19:20,607,507...20,611,316
|
|
G |
Ccdc127 |
coiled-coil domain containing 127 |
increases expression |
EXP |
Cocaine results in increased expression of CCDC127 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 1:31,538,088...31,545,573
Ensembl chr 1:31,539,215...31,545,559
|
|
G |
Ccdc174 |
coiled-coil domain containing 174 |
affects expression |
EXP |
Cocaine affects the expression of CCDC174 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 4:123,760,708...123,787,529
Ensembl chr 4:123,760,743...123,787,528
|
|
G |
Ccdc73 |
coiled-coil domain containing 73 |
decreases expression |
EXP |
Cocaine results in decreased expression of CCDC73 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:94,848,775...94,989,984
Ensembl chr 3:94,848,823...94,986,263
|
|
G |
Ccdc88a |
coiled coil domain containing 88A |
increases expression |
EXP |
Cocaine results in increased expression of CCDC88A mRNA |
CTD |
PMID:17898221 |
|
NCBI chr14:113,771,093...113,936,376
Ensembl chr14:113,867,209...113,932,263
|
|
G |
Ccdc93 |
coiled-coil domain containing 93 |
increases expression |
EXP |
Cocaine results in increased expression of CCDC93 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr13:37,400,455...37,473,973
Ensembl chr13:37,400,476...37,468,840
|
|
G |
Cckbr |
cholecystokinin B receptor |
decreases expression increases response to substance |
ISO |
Cocaine results in decreased expression of CCKBR mRNA CCKBR protein results in increased susceptibility to Cocaine |
CTD |
PMID:11403953 PMID:18000554 |
|
NCBI chr 1:170,262,218...170,272,298
Ensembl chr 1:170,262,156...170,272,298
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion increases expression multiple interactions |
ISO EXP |
Cocaine results in increased secretion of CCL2 protein Cocaine results in increased expression of CCL2 mRNA; Cocaine results in increased expression of CCL2 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; AG 1879 inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; Cocaine promotes the reaction [RELA protein binds to CCL2 promoter]; methyl-beta-cyclodextrin inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; pyrazolanthrone inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; RELA mutant form inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; SC 514 inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; SIGMAR1 mutant form inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; U 0126 inhibits the reaction [Cocaine results in increased expression of CCL2 protein] |
CTD |
PMID:10065903 PMID:20354174 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Cocaine results in increased secretion of CCL3 protein |
CTD |
PMID:10065903 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Cocaine results in decreased expression of CCN2 mRNA; Cocaine results in decreased expression of CCN2 protein |
CTD |
PMID:18000554 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccn3 |
cellular communication network factor 3 |
increases expression |
EXP |
Cocaine results in increased expression of CCN3 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 7:94,375,134...94,382,154
Ensembl chr 7:94,375,020...94,383,024
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO EXP |
Cocaine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:18593214 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnd1 |
cyclin D1 |
affects expression |
EXP |
Cocaine affects the expression of CCND1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd3 |
cyclin D3 |
affects expression |
EXP |
Cocaine affects the expression of CCND3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccnl1 |
cyclin L1 |
increases expression |
EXP |
Cocaine results in increased expression of CCNL1 mRNA |
CTD |
PMID:16076954 |
|
NCBI chr 2:157,747,295...157,759,838
Ensembl chr 2:157,747,542...157,759,838
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
affects expression increases response to substance |
EXP ISO |
Cocaine affects the expression of CCR2 mRNA CCR2 results in increased susceptibility to Cocaine |
CTD |
PMID:20187946 PMID:20354174 |
|
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
Cocaine results in increased expression of CCR5 protein |
CTD |
PMID:16204638 |
|
NCBI chr 8:133,192,398...133,215,599
Ensembl chr 8:133,197,032...133,215,614
|
|
G |
Ccser1 |
coiled-coil serine-rich protein 1 |
affects response to substance |
ISO |
CCSER1 gene SNP affects the susceptibility to Cocaine |
CTD |
PMID:18438686 |
|
NCBI chr 4:91,235,885...92,516,800
Ensembl chr 4:91,373,942...91,972,325
|
|
G |
Cct2 |
chaperonin containing TCP1 subunit 2 |
affects expression |
EXP |
Cocaine affects the expression of CCT2 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 7:60,106,532...60,122,779
Ensembl chr 7:60,109,974...60,122,805
|
|
G |
Cd180 |
CD180 molecule |
decreases expression |
EXP |
Cocaine results in decreased expression of CD180 mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 2:32,820,275...32,833,223
Ensembl chr 2:32,820,322...32,833,125
|
|
G |
Cd276 |
Cd276 molecule |
affects expression |
EXP |
Cocaine affects the expression of CD276 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 8:63,312,060...63,350,411
Ensembl chr 8:63,318,019...63,350,269
|
|
G |
Cd4 |
Cd4 molecule |
multiple interactions |
ISO |
[Cocaine co-treated with FOS protein mutant form] results in decreased expression of CD4 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr 4:157,381,862...157,408,357
Ensembl chr 4:157,383,052...157,408,176
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
decreases expression |
ISO |
Cocaine results in decreased expression of CD44 mRNA |
CTD |
PMID:18000554 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd47 |
Cd47 molecule |
affects expression |
EXP |
Cocaine affects the expression of CD47 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr11:53,511,485...53,575,754
Ensembl chr11:53,514,595...53,575,175
|
|
G |
Cd74 |
CD74 molecule |
affects expression |
EXP |
Cocaine affects the expression of CD74 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
|
|
G |
Cd81 |
Cd81 molecule |
increases response to substance increases expression affects response to substance |
ISO EXP |
CD81 protein results in increased susceptibility to Cocaine Cocaine results in increased expression of CD81 mRNA CD81 protein affects the susceptibility to Cocaine |
CTD |
PMID:11178868 PMID:12113778 PMID:15715673 |
|
NCBI chr 1:216,237,663...216,253,460
Ensembl chr 1:216,237,697...216,253,311
|
|
G |
Cd93 |
CD93 molecule |
decreases expression |
EXP |
Cocaine results in decreased expression of CD93 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:142,778,798...142,783,774
Ensembl chr 3:142,778,770...142,783,774
|
|
G |
Cdc14b |
cell division cycle 14B |
decreases expression |
EXP |
Cocaine results in decreased expression of CDC14B mRNA |
CTD |
PMID:17898221 |
|
NCBI chr17:1,709,703...1,797,732
Ensembl chr17:1,703,943...1,797,750
|
|
G |
Cdc25a |
cell division cycle 25A |
increases expression |
EXP |
Cocaine results in increased expression of CDC25A mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 8:117,953,223...117,971,552
Ensembl chr 8:117,953,444...117,971,519
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of CDH1 mRNA |
CTD |
PMID:12629581 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh16 |
cadherin 16 |
affects expression |
EXP |
Cocaine affects the expression of CDH16 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr19:568,329...578,513
Ensembl chr19:568,287...578,520
|
|
G |
Cdh17 |
cadherin 17 |
decreases expression |
ISO |
Cocaine results in decreased expression of CDH17 mRNA |
CTD |
PMID:12629581 |
|
NCBI chr 5:25,354,187...25,443,675
Ensembl chr 5:25,391,115...25,443,718
|
|
G |
Cdk18 |
cyclin-dependent kinase 18 |
affects expression |
EXP |
Cocaine affects the expression of CDK18 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr13:48,893,525...48,926,673
Ensembl chr13:48,893,412...48,927,483
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
affects expression |
ISO |
Cocaine affects the expression of CDK4 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
affects expression increases expression decreases expression |
EXP |
Cocaine affects the expression of CDK5 mRNA; Cocaine affects the expression of CDK5 protein Cocaine results in increased expression of CDK5 mRNA; Cocaine results in increased expression of CDK5 protein Cocaine results in decreased expression of CDK5 protein |
CTD |
PMID:11268215 PMID:12787079 PMID:16263094 PMID:17339080 PMID:17680995 PMID:20187946 |
|
NCBI chr 4:7,282,945...7,287,427
Ensembl chr 4:7,282,948...7,288,383
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions increases expression decreases expression |
ISO EXP |
CDK5R1 protein inhibits the reaction [Cocaine affects the expression of FOS mRNA]; CDK5R1 protein inhibits the reaction [Cocaine results in increased expression of FOS protein]; CDK5R1 protein inhibits the reaction [Cocaine results in increased phosphorylation of CREB1 protein]; CDK5R1 protein inhibits the reaction [Cocaine results in increased phosphorylation of MAP2K1 protein]; CDK5R1 protein inhibits the reaction [Cocaine results in increased phosphorylation of MAP2K2 protein]; CDK5R1 protein inhibits the reaction [Cocaine results in increased phosphorylation of MAPK1 protein]; CDK5R1 protein inhibits the reaction [Cocaine results in increased phosphorylation of MAPK3 protein]; CDK5R1 protein inhibits the reaction [Cocaine results in increased phosphorylation of PPP1R1B protein] Cocaine results in increased expression of CDK5R1 mRNA; Cocaine results in increased expression of CDK5R1 protein Cocaine results in decreased expression of CDK5R1 protein |
CTD |
PMID:11268215 PMID:15665076 PMID:16263094 |
|
NCBI chr10:67,862,054...67,863,255
Ensembl chr10:67,862,054...67,863,255
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP |
Cocaine results in increased expression of CDKN1A mRNA |
CTD |
PMID:27899881 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Ceacam4 |
CEA cell adhesion molecule 4 |
affects expression |
EXP |
Cocaine affects the expression of CEACAM3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:81,643,809...81,650,085
Ensembl chr 1:81,643,816...81,650,094 Ensembl chr 1:81,643,816...81,650,094
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
EXP |
Cocaine results in increased expression of CEL mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions increases hydrolysis affects binding |
ISO |
CES1 protein results in increased metabolism of [Cocaine co-treated with Ethanol]; Cocaine inhibits the reaction [CES1 protein results in increased chemical synthesis of 6-O-monoacetylmorphine]; Cocaine inhibits the reaction [CES1 protein results in increased hydrolysis of 4-methylumbelliferyl acetate]; Cocaine inhibits the reaction [CES1 protein results in increased hydrolysis of Heroin] CES1 protein results in increased hydrolysis of Cocaine Cocaine binds to CES1 protein |
CTD |
PMID:8930175 PMID:9311626 PMID:12679808 PMID:12773168 PMID:25445008 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions decreases expression increases hydrolysis |
ISO |
Cocaine inhibits the reaction [CES2 protein results in increased chemical synthesis of 6-O-monoacetylmorphine]; Cocaine inhibits the reaction [CES2 protein results in increased chemical synthesis of Morphine]; Cocaine inhibits the reaction [CES2 protein results in increased hydrolysis of 6-O-monoacetylmorphine]; Cocaine inhibits the reaction [CES2 protein results in increased hydrolysis of Heroin] Cocaine results in decreased expression of CES2 mRNA CES2 protein results in increased hydrolysis of Cocaine |
CTD |
PMID:8930175 PMID:9169443 PMID:12629581 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cfh |
complement factor H |
decreases expression |
EXP |
Cocaine results in decreased expression of CFH mRNA |
CTD |
PMID:17898221 |
|
NCBI chr13:56,979,155...57,080,540
Ensembl chr13:56,978,607...57,080,622
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression |
ISO |
Cocaine affects the expression of CFLAR mRNA |
CTD |
PMID:15681117 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chfr |
checkpoint with forkhead and ring finger domains |
affects expression |
EXP |
Cocaine affects the expression of CHFR mRNA |
CTD |
PMID:20187946 |
|
NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
|
|
G |
Chn1 |
chimerin 1 |
affects expression |
EXP |
Cocaine affects the expression of CHN1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 3:60,512,360...60,668,413
Ensembl chr 3:60,513,077...60,611,924
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects expression |
EXP |
Cocaine affects the expression of CHRM4 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 3:80,833,272...80,841,165
Ensembl chr 3:80,833,272...80,841,006
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
decreases response to substance |
EXP |
CHRM5 mutant form results in decreased susceptibility to Cocaine |
CTD |
PMID:20393457 |
|
NCBI chr 3:103,966,451...104,018,815
Ensembl chr 3:103,966,451...104,018,861
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
EXP |
Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]] |
CTD |
PMID:10336510 |
|
NCBI chr 8:59,594,007...59,607,122
Ensembl chr 8:59,592,403...59,607,275
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] |
CTD |
PMID:10336510 |
|
NCBI chr 3:176,533,182...176,547,965
Ensembl chr 3:176,527,516...176,548,208
|
|
G |
Chrna5 |
cholinergic receptor nicotinic alpha 5 subunit |
decreases response to substance |
ISO |
CHRNA5 gene polymorphism results in decreased susceptibility to Cocaine |
CTD |
PMID:18519132 |
|
NCBI chr 8:59,561,817...59,590,172
Ensembl chr 8:59,561,721...59,590,172
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions increases response to substance |
EXP ISO |
Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] CHRNB2 protein results in increased susceptibility to Cocaine |
CTD |
PMID:10336510 PMID:11282258 |
|
NCBI chr 2:189,088,570...189,096,785
Ensembl chr 2:189,088,570...189,096,785
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
increases expression |
EXP |
Cocaine results in increased expression of CHRNE mRNA |
CTD |
PMID:27899881 |
|
NCBI chr10:57,238,960...57,246,750
Ensembl chr10:57,238,946...57,243,435
|
|
G |
Chtf8 |
chromosome transmission fidelity factor 8 |
decreases expression |
EXP |
Cocaine results in decreased expression of CHTF8 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr19:39,077,580...39,087,880
Ensembl chr19:39,077,580...39,087,880
|
|
G |
Churc1 |
churchill domain containing 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of CHURC1 mRNA |
CTD |
PMID:15009677 PMID:16710320 |
|
NCBI chr 6:99,817,439...99,831,574
Ensembl chr 6:99,817,431...99,831,576
|
|
G |
Ciao1 |
cytosolic iron-sulfur assembly component 1 |
affects expression |
EXP |
Cocaine affects the expression of CIAO1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 3:119,671,778...119,677,324
Ensembl chr 3:119,671,779...119,678,092
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
affects expression |
ISO |
Cocaine affects the expression of CIDEA mRNA |
CTD |
PMID:15681117 |
|
NCBI chr18:63,082,861...63,108,450
Ensembl chr18:63,098,144...63,108,051
|
|
G |
Cideb |
cell death-inducing DFFA-like effector b |
affects expression |
ISO |
Cocaine affects the expression of CIDEB mRNA |
CTD |
PMID:15681117 |
|
NCBI chr15:34,439,844...34,444,244
Ensembl chr15:34,439,876...34,444,244
|
|
G |
Cisd1 |
CDGSH iron sulfur domain 1 |
increases expression |
EXP |
Cocaine results in increased expression of CISD1 protein |
CTD |
PMID:25100957 |
|
NCBI chr20:18,493,538...18,506,923
Ensembl chr20:18,493,538...18,506,912
|
|
G |
Cisd2 |
CDGSH iron sulfur domain 2 |
increases expression |
EXP |
Cocaine results in increased expression of CISD2 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 2:240,586,754...240,611,560
Ensembl chr 2:240,586,754...240,611,560
|
|
G |
Cited4 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 |
decreases expression |
EXP |
Cocaine results in decreased expression of CITED4 mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 5:139,597,731...139,598,622
Ensembl chr 5:139,597,731...139,598,622
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
ISO |
Cocaine results in increased secretion of [CKB protein binds to CKM protein] |
CTD |
PMID:12359538 |
|
NCBI chr 6:136,142,956...136,145,838
Ensembl chr 6:136,142,956...136,145,837
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
ISO |
Cocaine results in increased secretion of [CKB protein binds to CKM protein] |
CTD |
PMID:12359538 |
|
NCBI chr 1:80,321,507...80,331,841
Ensembl chr 1:80,321,585...80,331,841
|
|
G |
Ckmt1 |
creatine kinase, mitochondrial 1 |
affects expression |
EXP |
Cocaine affects the expression of CKMT1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 3:113,318,559...113,324,459
Ensembl chr 3:113,318,563...113,324,461
|
|
G |
Clcn7 |
chloride voltage-gated channel 7 |
affects expression |
EXP |
Cocaine affects the expression of CLCN7 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr10:14,492,844...14,518,167
Ensembl chr10:14,492,844...14,516,894
|
|
G |
Cldn11 |
claudin 11 |
decreases expression |
ISO |
Cocaine results in decreased expression of CLDN11 mRNA |
CTD |
PMID:18357522 |
|
NCBI chr 2:115,823,541...115,836,846
Ensembl chr 2:115,823,538...115,836,846
|
|
G |
Clec4f |
C-type lectin domain family 4, member F |
affects expression |
EXP |
Cocaine affects the expression of CLEC4F mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 4:115,322,300...115,332,021
Ensembl chr 4:115,322,291...115,332,052
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of CLIC1 mRNA |
CTD |
PMID:18000554 |
|
NCBI chr20:5,040,314...5,049,166
Ensembl chr20:5,040,337...5,049,166
|
|
G |
Clip1 |
CAP-GLY domain containing linker protein 1 |
increases expression |
ISO |
Cocaine results in increased expression of CLIP1 mRNA |
CTD |
PMID:18000554 |
|
NCBI chr12:38,345,203...38,452,650
Ensembl chr12:38,345,456...38,452,652
|
|
G |
Clk1 |
CDC-like kinase 1 |
increases expression multiple interactions |
ISO |
Cocaine results in increased expression of CLK1 mRNA FOS protein mutant form inhibits the reaction [Cocaine results in increased expression of CLK1 mRNA] |
CTD |
PMID:18355967 |
|
NCBI chr 9:65,296,777...65,308,017
Ensembl chr 9:65,296,778...65,307,995
|
|
G |
Clk4 |
CDC-like kinase 4 |
increases expression |
ISO |
Cocaine results in increased expression of CLK4 mRNA |
CTD |
PMID:20056891 |
|
NCBI chr10:36,715,565...36,733,473
Ensembl chr10:36,715,565...36,733,133
|
|
G |
Clock |
clock circadian regulator |
increases expression |
ISO |
Cocaine results in increased expression of CLOCK mRNA |
CTD |
PMID:15994025 |
|
NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218
|
|
G |
Cltb |
clathrin, light chain B |
decreases expression |
ISO |
Cocaine results in decreased expression of CLTB mRNA |
CTD |
PMID:12629581 PMID:15009677 |
|
NCBI chr17:10,537,348...10,554,999
Ensembl chr17:10,537,365...10,554,989
|
|
G |
Clybl |
citramalyl-CoA lyase |
increases expression |
EXP |
Cocaine results in increased expression of CLYBL protein |
CTD |
PMID:25100957 |
|
NCBI chr15:108,608,203...108,838,222
Ensembl chr15:108,608,204...108,838,235
|
|
G |
Cnbd2 |
cyclic nucleotide binding domain containing 2 |
increases expression |
EXP |
Cocaine results in increased expression of CNBD2 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 3:152,382,245...152,448,105
Ensembl chr 3:152,402,520...152,465,228
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
increases expression |
ISO |
Cocaine results in increased expression of CNKSR2 mRNA |
CTD |
PMID:15009677 |
|
NCBI chr X:39,711,001...39,953,860
Ensembl chr X:39,711,201...39,951,847
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects response to substance increases activity decreases response to substance multiple interactions |
ISO |
CNR1 gene polymorphism affects the susceptibility to Cocaine; CNR1 gene SNP affects the susceptibility to Cocaine; CNR1 polymorphism affects the susceptibility to Cocaine Cocaine results in increased activity of CNR1 protein CNR1 mutant form results in decreased susceptibility to Cocaine CNR1 gene mutant form inhibits the reaction [Cocaine results in increased phosphorylation of PPP1R1B protein]; CNR1 mutant form inhibits the reaction [Cocaine results in increased expression of FOS protein]; CNR1 mutant form inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 mutant form inhibits the reaction [Cocaine results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:9106242 PMID:16314880 PMID:17596442 PMID:19052543 PMID:20554863 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
increases expression |
ISO |
Cocaine results in increased expression of CNR2 mRNA |
CTD |
PMID:18286196 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Cobll1 |
cordon-bleu WH2 repeat protein-like 1 |
increases expression |
ISO |
Cocaine results in increased expression of COBLL1 mRNA |
CTD |
PMID:27506785 |
|
NCBI chr 3:51,137,104...51,298,956
Ensembl chr 3:51,137,076...51,297,852
|
|
G |
Coil |
coilin |
affects expression |
EXP |
Cocaine affects the expression of COIL mRNA |
CTD |
PMID:20187946 |
|
NCBI chr10:76,320,676...76,336,169
Ensembl chr10:76,320,041...76,341,418
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
affects expression |
EXP |
Cocaine affects the expression of COL15A1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 5:62,840,360...62,950,240
Ensembl chr 5:64,476,317...64,542,645 Ensembl chr 5:64,476,317...64,542,645
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
EXP |
Cocaine results in increased expression of COL1A1 mRNA |
CTD |
PMID:9455993 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression |
EXP |
Cocaine results in increased expression of COL3A1 mRNA |
CTD |
PMID:9455993 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Coq6 |
coenzyme Q6 monooxygenase |
affects expression |
EXP |
Cocaine affects the expression of COQ6 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 6:108,076,393...108,087,782
Ensembl chr 6:108,076,306...108,087,696
|
|
G |
Coro7 |
coronin 7 |
multiple interactions |
ISO |
[Cocaine co-treated with FOS protein mutant form] results in decreased expression of CORO7 mRNA |
CTD |
PMID:18355967 |
|
NCBI chr10:11,090,200...11,144,289
Ensembl chr10:11,090,314...11,143,881 Ensembl chr10:11,090,314...11,143,881
|
|
G |
Cox20 |
cytochrome c oxidase assembly factor COX20 |
decreases expression |
EXP |
Cocaine results in decreased expression of COX20 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr13:96,219,853...96,224,023
Ensembl chr13:96,219,853...96,224,023
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
affects expression |
EXP |
Cocaine affects the expression of COX5A mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 8:62,298,358...62,309,765
Ensembl chr 8:62,298,358...62,309,765
|
|
G |
Cox6a1 |
cytochrome c oxidase subunit 6A1 |
affects expression increases expression |
EXP |
Cocaine affects the expression of COX6A1 mRNA Cocaine results in increased expression of COX6A1 protein |
CTD |
PMID:20187946 PMID:25100957 |
|
NCBI chr12:47,024,442...47,027,495
Ensembl chr12:47,024,442...47,027,495
|
|
G |
Cox6c |
cytochrome c oxidase subunit 6C |
decreases expression |
ISO |
Cocaine results in decreased expression of COX6C mRNA |
CTD |
PMID:12629581 |
|
NCBI chr 7:74,723,177...74,735,650
Ensembl chr 7:74,723,179...74,735,650
|
|
G |
Cox7b |
cytochrome c oxidase subunit 7B |
affects expression |
EXP |
Cocaine affects the expression of COX7B mRNA |
CTD |
PMID:20187946 |
|
NCBI chr X:77,065,427...77,071,676
Ensembl chr X:77,065,397...77,071,676
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
affects expression |
EXP |
Cocaine affects the expression of COX8A mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:222,466,575...222,468,896
Ensembl chr 1:222,466,575...222,468,896
|
|
G |
Cplx1 |
complexin 1 |
affects expression |
EXP |
Cocaine affects the expression of CPLX1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr14:2,194,895...2,226,610
Ensembl chr14:2,194,933...2,226,598
|
|
G |
Cpne8 |
copine 8 |
increases expression |
EXP |
Cocaine results in increased expression of CPNE8 mRNA |
CTD |
PMID:17898221 |
|
NCBI chr 7:131,623,180...131,798,236
Ensembl chr 7:131,623,181...131,798,236
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
affects expression increases phosphorylation multiple interactions affects phosphorylation increases expression |
EXP ISO |
Cocaine affects the expression of CREB1 mRNA Cocaine results in increased phosphorylation of CREB1 protein CDK5R1 protein inhibits the reaction [Cocaine results in increased phosphorylation of CREB1 protein]; Cocaine inhibits the reaction [CREB1 protein binds to BDNF promoter]; N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine inhibits the reaction [Cocaine results in increased expression of CREB1 protein]; RPS6KA3 gene mutant form inhibits the reaction [Cocaine results in increased phosphorylation of CREB1 protein]; SL 327 inhibits the reaction [Cocaine results in increased phosphorylation of CREB1 protein] Cocaine affects the phosphorylation of CREB1 protein Betaxolol affects the reaction [Cocaine affects the phosphorylation of CREB1 protein]; Cocaine affects the reaction [CREB1 modified form binds to BDNF promoter]; Cocaine promotes the reaction [RPS6KA1 protein binds to CREB1 protein]; Cocaine results in increased phosphorylation of and results in increased activity of CREB1 protein; U 0126 inhibits the reaction [Cocaine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:12595601 PMID:15470197 PMID:15665076 PMID:16219028 PMID:16339038 PMID:16710312 PMID:18596687 PMID:20187946 PMID:20810894 PMID:24358339 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
EXP |
Cocaine results in increased expression of CREBBP mRNA |
CTD |
PMID:17898221 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Crebrf |
CREB3 regulatory factor |
increases expression |
EXP |
Cocaine results in increased expression of CREBRF mRNA |
CTD |
PMID:17898221 |
|
NCBI chr10:16,693,846...16,753,162
Ensembl chr10:16,694,792...16,752,205
|
|
G |
Crem |
cAMP responsive element modulator |
affects expression increases expression |
ISO EXP |
Cocaine affects the expression of CREM mRNA Cocaine results in increased expression of CREM mRNA |
CTD |
PMID:18355967 PMID:27899881 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions affects expression |
EXP |
Betaxolol affects the reaction [Cocaine affects the expression of CRH mRNA]; Cocaine affects the reaction [CRH protein affects the secretion of Excitatory Amino Acid Agents]; SCH 23390 affects the reaction [Cocaine affects the expression of CRH mRNA] Cocaine affects the expression of CRH mRNA; Cocaine affects the expression of CRH protein |
CTD |
PMID:7796157 PMID:11597771 PMID:12782395 PMID:15930388 PMID:18596687 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
increases expression |
EXP |
Cocaine results in increased expression of CRHBP mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 2:25,141,471...25,153,334
Ensembl chr 2:25,141,471...25,153,334
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
increases expression |
EXP |
Cocaine results in increased expression of CRHR1 protein |
CTD |
PMID:17079348 |
|
NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645
|
|
G |
Crip2 |
cysteine-rich protein 2 |
affects expression |
EXP |
Cocaine affects the expression of CRIP2 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 6:137,953,545...137,958,491
Ensembl chr 6:137,953,545...137,958,490
|
|
G |
Crispld1 |
cysteine-rich secretory protein LCCL domain containing 1 |
decreases expression |
EXP |
Cocaine results in decreased expression of CRISPLD1 mRNA |
CTD |
PMID:27899881 |
|
NCBI chr 5:663,750...711,033
Ensembl chr 5:670,754...711,033
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
Cocaine results in increased expression of CRP protein |
CTD |
PMID:11988210 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Crtac1 |
cartilage acidic protein 1 |
affects expression |
EXP |
Cocaine affects the expression of CRTAC1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr 1:261,527,009...261,669,614
Ensembl chr 1:261,514,141...261,669,586
|
|
G |
Crtc1 |
CREB regulated transcription coactivator 1 |
multiple interactions |
EXP |
[[Cocaine results in increased expression of MIR212 mRNA] which results in increased activity of RAF1 protein] which results in increased expression of CRTC1 protein |
CTD |
PMID:20613834 |
|
NCBI chr16:20,740,746...20,798,145
Ensembl chr16:20,740,826...20,794,039
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of CRY1 mRNA |
CTD |
PMID:15994025 |
|
NCBI chr 7:24,534,593...24,634,098
Ensembl chr 7:24,534,615...24,634,097
|
|
G |
Cry2 |
cryptochrome circadian regulator 2 |
decreases expression |
ISO |
Cocaine results in decreased expression of CRY2 mRNA |
CTD |
PMID:15994025 |
|
NCBI chr 3:81,314,151...81,344,143
Ensembl chr 3:81,314,149...81,344,110
|
|
G |
Cryab |
crystallin, alpha B |
decreases expression increases expression |
ISO EXP |
Cocaine results in decreased expression of CRYAB mRNA Cocaine results in increased expression of CRYAB mRNA |
CTD |
PMID:15009677 PMID:27899881 |
|
NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
|
|
G |
Crybb2 |
crystallin, beta B2 |
decreases expression |
ISO |
Cocaine results in decreased expression of CRYBB2 mRNA |
CTD |
PMID:15009677 |
|
NCBI chr12:49,577,580...49,588,555
Ensembl chr12:49,578,633...49,588,555
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
affects expression decreases expression |
EXP |
Cocaine affects the expression of CSAD mRNA Cocaine results in decreased expression of CSAD protein |
CTD |
PMID:20187946 PMID:25100957 |
|
NCBI chr 7:143,781,520...143,810,880
Ensembl chr 7:143,781,702...143,793,970
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
decreases expression |
EXP |
Cocaine results in decreased expression of CSF2RA mRNA |
CTD |
PMID:17898221 |
|
NCBI chr14:1,462,292...1,467,264
Ensembl chr14:1,462,358...1,467,264
|
|
G |
Csn3 |
casein kappa |
affects expression |
EXP |
Cocaine affects the expression of CSN3 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr14:21,803,738...21,810,291
Ensembl chr14:21,803,735...21,810,314
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
decreases expression |
EXP |
Cocaine results in decreased expression of CSNK2A1 mRNA |
CTD |
PMID:12117546 |
|
NCBI chr 3:147,713,808...147,760,375
Ensembl chr 3:147,713,821...147,757,862
|
|
G |
Cspg5 |
chondroitin sulfate proteoglycan 5 |
affects expression |
EXP |
Cocaine affects the expression of CSPG5 mRNA; Cocaine affects the expression of CSPG5 protein |
CTD |
PMID:12358776 |
|
NCBI chr 8:118,333,695...118,348,040
Ensembl chr 8:118,333,706...118,347,582
|
|
G |
Csrp2 |
cysteine and glycine-rich protein 2 |
decreases expression |
ISO |
Cocaine results in decreased expression of CSRP2 mRNA |
CTD |
PMID:18000554 |
|
NCBI chr 7:53,630,675...53,649,309
Ensembl chr 7:53,630,621...53,649,310
|
|
G |
Ctdnep1 |
CTD nuclear envelope phosphatase 1 |
affects expression |
EXP |
Cocaine affects the expression of CTDNEP1 mRNA |
CTD |
PMID:20187946 |
|
NCBI chr10:56,590,822...56,600,235
Ensembl chr10:56,591,292...56,600,232
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects expression multiple interactions |
EXP |
Cocaine affects the expression of CTNNB1 mRNA Cocaine deficiency promotes the reaction [SMARCA4 protein binds to CTNNB1 promoter] |
CTD |
PMID:20187946 PMID:27422367 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
decreases expression |
ISO |
Cocaine results in decreased expression of CTNNBIP1 mRNA |
CTD |
PMID:18000554 |
|
NCBI chr 5:166,464,170...166,513,030
Ensembl chr 5:166,464,252...166,513,027
|
|
G |
Ctnnd2 |
catenin delta 2 |
decreases expression increases expression |
ISO EXP |
Cocaine results in decreased expression of CTNND2 mRNA Cocaine results in increased expression of CTNND2 mRNA |
CTD |
PMID:12629581 PMID:16076954 |
|
NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315
|
|
G |
Ctrl |
chymotrypsin-like |
affects expression increases expression |
EXP |
Cocaine affects the expression of CTRL mRNA Cocaine results in increased expression of CTRL mRNA |
CTD |
PMID:20187946 PMID:27899881 |
|
NCBI chr19:37,905,864...37,907,714
Ensembl chr19:37,905,864...37,907,714
|
|
G |
Ctsb |
cathepsin B |
affects expression multiple interactions increases expression |
ISO |
Cocaine affects the expression of CTSB mRNA FOS protein mutant form inhibits the reaction [Cocaine results in increased expression of CTSB mRNA] |
CTD |
PMID:15681117 PMID:18355967 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Ctsd |
cathepsin D |
affects expression increases expression |
ISO EXP |
Cocaine affects the expression of CTSD mRNA Cocaine results in increased expression of CTSD protein |
CTD |
PMID:15681117 PMID:25100957 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Cuedc1 |
CUE domain containing 1 |
multiple interactions |
ISO |
HDAC5 affects the reaction [Cocaine affects the expression of CUEDC1 mRNA] |
CTD |
PMID:17988634 |
|
NCBI chr10:75,495,817...75,516,280
Ensembl chr10:75,495,817...75,516,304
|
|
G |
Cul4b |
cullin 4B |
increases expression |
ISO |
Cocaine results in increased expression of CUL4B mRNA |
CTD |
PMID:15009677 |
|
NCBI chr X:124,831,391...124,870,329
Ensembl chr X:124,832,628...124,870,329
|
|
G |
Cwf19l2 |
CWF19 like cell cycle control factor 2 |
increases expression |
EXP |
Cocaine results in increased expression of CWF19L2 mRNA |
CTD |
|